(HSGX) to Present at 18th Annual BIO CEO & Investor Conference

WALTHAM, Mass., Jan. 26, 2016  — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley, President and Chief Executive Officer of Histogenics, will be presenting at the 18^th Annual BIO CEO & Investor Conference on Tuesday February 9, 2016 at 3:30PM EST during the conference’s Regenerative Medicine track at the Waldorf Astoria in New York, NY.  The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies.

This presentation will be webcast live and may be accessed by visiting the Investor Relations section of Histogenics’ website at www.histogenics.com.  The webcast will be available on Histogenics’ website for 30 days following the conference.

About Histogenics Corporation

Histogenics is a leading regenerative medicine company developing and commercializing products in the musculoskeletal segment of the marketplace. Histogenics’ regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions to treat musculoskeletal-related conditions. Histogenics’ first investigational product candidate, NeoCart®, is currently in Phase 3 clinical development.  NeoCart is an autologous cell therapy designed to treat cartilage defects in the knee using the patient’s own cells.  Knee cartilage defects represent a significant opportunity in the United States, with an estimated 500,000 or more applicable procedures each year.  NeoCart is designed to exhibit characteristics of articular, hyaline cartilage prior to and upon implantation into the knee and therefore does not rely on the body to make new cartilage, characteristics not exhibited in other current treatment options.  For more information, please visit www.histogenics.com.

Contact:

Investor Relations
Tel: +1 (781) 547-7909
InvestorRelations@histogenics.com

(AMBC) Settles RMBS Litigation Against (JPM) for $995 Million

NEW YORK, Jan. 26, 2016  — Ambac Financial Group, Inc. (Nasdaq:AMBC) (“Ambac”), a holding company whose subsidiaries, including Ambac Assurance Corporation (“AAC”), provide financial guarantees and other financial services, today announced that AAC and the Segregated Account of AAC have settled their RMBS-related disputes and litigation against JP Morgan Chase & Co. and certain of its affiliates (collectively “JP Morgan”).

Pursuant to the settlement, JP Morgan will pay AAC $995 million in cash in return for releases of all of AAC’s claims against JP Morgan arising from certain RMBS transactions insured by AAC.  AAC has also agreed to withdraw its objections to JP Morgan’s global RMBS settlement with RMBS trustees.

Commenting on today’s announcement, Nader Tavakoli, Ambac’s President and Chief Executive Officer, said, “We are delighted to bring our RMBS-related litigation against JP Morgan to a successful conclusion.  Today’s announcement validates our resolve and reinforces our confidence in our remaining RMBS-related cases.  This settlement will have a positive impact on our fourth quarter 2015 operating results, as well as our claims paying resources.  I want to thank our very capable legal and RMBS teams for their hard work and dedication in achieving this settlement.  Today’s announcement is but one example of our proactive efforts to address portfolio losses and enhance value for our stakeholders.”

The financial impact of the settlement and other related information will be described in Ambac’s fourth quarter 2015 earnings release and 2015 Form 10-K filed with the SEC.

Forward-Looking Statements
Certain statements in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ, possibly materially, from those included in these statements due to a variety of factors. Important factors that could cause our results to differ, possibly materially, from those indicated in the forward-looking statements include, among others, those discussed under “Risk Factors” in Part I, Item 1A of Ambac’s 2014 Annual Report on Form 10-K and in Part II, Item 1A of each of our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2015, June 30, 2015, and September 30, 2015.

About Ambac
Ambac Financial Group, Inc., (“Ambac”), headquartered in New York City, is a holding company whose subsidiaries, including its principal operating subsidiary, Ambac Assurance Corporation (“AAC”), Everspan Financial Guarantee Corp., and Ambac Assurance UK Limited, provide financial guarantees and other financial services to clients in both the public and private sectors globally. AAC, including the Segregated Account of AAC (in rehabilitation), is a guarantor of public finance and structured finance obligations. Ambac is also selectively exploring opportunities involving the acquisition and/or development of new businesses. Ambac‘s common stock trades on the NASDAQ Global Select Market under the symbol “AMBC”.  The Amended and Restated Certificate of Incorporation of Ambac contains substantial restrictions on the ability to transfer Ambac’s common stock. Subject to limited exceptions, any attempted transfer of common stock shall be prohibited and void to the extent that, as a result of such transfer (or any series of transfers of which such transfer is a part), any person or group of persons shall become a holder of 5% or more of Ambac’s common stock.  Ambac is committed to providing timely and accurate information to the investing public, consistent with our legal and regulatory obligations. To that end, we use our website to convey information about our businesses, including the anticipated release of quarterly financial results, quarterly financial, statistical and business-related information, and the posting of updates to the status of certain primary residential mortgage backed securities litigations. For more information, please go to www.ambac.com.

Abbe F. Goldstein, CFA
Managing Director, Investor Relations and Corporate Communications
(212) 208-3222
agoldstein@ambac.com

(SGOC) Signed an Exclusive Agency Agreement in Macau

SHENZHEN, China, Jan. 26, 2016  — SGOCO Group, Ltd. (Nasdaq: SGOC) (“SGOCO” or the “Company”), a company focused on product design, distribution and brand development in the Chinese display and computer product market, today announced that BOCA International Limited (“BOCA”), the Company’s recently-acquired subsidiary, has signed a long-term, primary and exclusive agency agreement with Macau Jinyi Technology Co., Ltd (“Macau Jinyi”). Under the terms of the agreement, BOCA authorized Macau Jinyi to exclusively develop and marketing the BOCA branded energy saving and environmental protection products and technologies in Macau, China.

Macau Jinyi is an affiliate of Macau Far East International Group which is a real-estate developer in Macau. As an important part of Macau Far East, Macau Jinyi is currently promoting its electric tour bus plan to Macau government and local casinos and resorts in an endeavor to replace the traditional buses and thus reduce the carbon-dioxide emission and improve the air quality in Macau. This is a niche market for SGOCO to generate sizable revenue.

BOCA collaborates Macau Jinyi in the development of a cooling and heating system that is an energy saving and environmentally friendly technology which could massively reduce the pollution emission at hotels and commercial buildings as well as cut down the expense on electricity. To date, BOCA provided the technology to various clients like government administration buildings, hospitals, resorts, shopping malls and indoor infrastructure. According to preliminary statistics, some large resorts spent $100-150 million to pay their electricity bills annually and BOCA saves more than 30% on energy expenditures with its advanced technology. The lifetime of the product is 15 years and then they can be recycled which provides economic benefits.

SGOCO could generate a total estimated value of at least $77 million in revenue within the next 3 years by providing services to casinos and resorts, government buildings and shopping malls in Macau.

Regarding the acquisition of BOCA, Mr. Shi-Bin Xie, Chief Executive Officer of SGOCO, commented, “We achieved initial results at the business transformation level and the company will continue to up its head to the energy saving and environmental protection target.”

About SGOCO Group, Ltd.

SGOCO Group, Ltd. is focused on product design, brand development and distribution in the Chinese display and computer product market. SGOCO sells its products and services in the Chinese market and abroad. For more information about SGOCO, please visit our investor relations website:

http://www.sgocogroup.com

For investor and media inquiries, please contact:
SGOCO Group, Ltd.
Tony Zhong
Vice President of Finance
Tel: +86-755-2697-8199 ext:7500
Email: ir@sgoco.com

Safe Harbor and Informational Statement

This announcement contains “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, those with respect to the objectives, plans and strategies of the Company set forth herein and those preceded by or that include the words “believe,” “expect,” “anticipate,” “future,” “will,” “intend,” “plan,” “estimate” or similar expressions, are “forward-looking statements”. Forward-looking statements in this release include, without limitation, the effectiveness of the Company’s multiple-brand, multiple channel strategy and the transitioning of its product development and sales focus and to a “light-asset” model, Although the Company’s management believes that such forward-looking statements are reasonable, it cannot guarantee that such expectations are, or will be, correct. These forward looking statements involve a number of risks and uncertainties, which could cause the Company’s future results to differ materially from those anticipated. These forward-looking statements can change as a result of many possible events or factors not all of which are known to the Company, which may include, without limitation, our ability to have effective internal control over financial reporting; our success in designing and distributing products under brands licensed from others; management of sales trend and client mix; possibility of securing loans and other financing without efficient fixed assets as collaterals; changes in government policy in China; China’s overall economic conditions and local market economic conditions; our ability to expand through strategic acquisitions and establishment of new locations; compliance with government regulations; legislation or regulatory environments; geopolitical events, and other events and/or risks outlined in SGOCO’s filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F and other filings. All information provided in this press release and in the attachments is as of the date of the issuance, and SGOCO does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

(CORI) to Present at LEERINK Partners 5th Annual Global Healthcare Conference

MENLO PARK, Calif., Jan. 26, 2016  — Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Peter Staple, Corium’s President and Chief Executive Officer, will present at the LEERINK Partners 5^th Annual Global Healthcare Conference in New York City on Wednesday, February 10, 2016 at 3:30 p.m. Eastern time.

A live audio broadcast of Corium’s presentation may be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.coriumgroup.com.  A webcast will be archived on the Corium website for two weeks following the presentation.

About Corium

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company’s broad experience in advanced transdermal and transmucosal delivery systems.  Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Teva Pharmaceuticals, Par Pharmaceutical and Procter & Gamble.  The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor^®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins.  The company’s late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics that is currently in Phase 3 trials, and additional transdermal products that are being developed with Teva.  Corium has multiple proprietary programs in preclinical and clinical development for the treatment of osteoporosis and neurological disorders.  For further information, please visit www.coriumgroup.com.

Corplex™ and MicroCor^® are registered trademarks of Corium International, Inc.
Crest^® Whitestrips is a registered trademark of The Procter & Gamble Company.

Investor and Media Contact:
Karen L. Bergman
BCC Partners
kbergman@bccpartners.com
(650) 575-1509

(CAPN) Signs Exclusive Nationwide Distribution Agreement for CoSense®

Capnia and Bemes Enter Collaboration Targeting Hospitals and Physicians

REDWOOD CITY, Calif., Jan. 26, 2016  — Capnia, Inc. (NASDAQ:CAPN), a diversified healthcare company that develops innovative diagnostics, devices and therapeutics addressing unmet medical needs, today announced that it has entered into an exclusive distribution agreement with Bemes, Inc., a leading medical equipment Master Distributor, to market and distribute the CoSense^® End-Tidal Carbon Monoxide (ETCO) Monitor and Precision Sampling Sets (PSS).

Under the terms of the agreement, effective January 26, 2016, Bemes will have the exclusive right for sales, marketing, distribution and field service activities for CoSense in the United States.  Bemes and its network of sub distributors will allow comprehensive nationwide distribution of CoSense with 44 sales representatives covering virtually every state. Bemes has placed orders for multiple CoSense monitors, as well as corresponding supplies of PSS in conjunction with the execution of the agreement.

“Bemes is a leading medical equipment sales channel with a strong go-to market capability and extensive relationships with top-tier hospitals throughout the United States. Their substantial on-ground presence and experience in distribution to neonatology centers will be critical for accelerating adoption of CoSense^®,” said Anish Bhatnagar, MD, Chief Executive Officer of Capnia. “For over a decade, the American Academy of Pediatrics (AAP) has recommended the use of ETCO measurement to confirm the presence or absence of hemolysis in neonates and CoSense is the only commercially available device that can achieve this.  With a world-class sales team and a demonstrated record of success in sales and marketing of innovative medical equipment, Bemes is the ideal partner to drive the long-term growth of CoSense and we look forward to a successful collaboration.”

“This agreement with Capnia is a key step in our pursuit of new commercial opportunities for high-growth areas, like neonatology, that can leverage Bemes’ extensive distribution capabilities,” said Mark Spreitler, President, Bemes, Inc. “CoSense represents a leading-edge tool to help hospitals and physicians non-invasively detect hemolysis using a simple breath test at the bedside.  We see significant clinical value in CoSense and we look forward to using our broad commercial capabilities to advance this important product.”

About Capnia

Capnia, Inc. is a diversified healthcare company that develops innovative diagnostics, devices and therapeutics addressing unmet medical needs. Capnia’s lead commercial product, CoSense, is based on the Sensalyze™ Technology Platform. It is a portable, non-invasive device that rapidly and accurately measures carbon monoxide (CO) in exhaled breath. CoSense has 510(k) clearance for sale in the U.S. and has received CE Mark certification for sale in the European Union. CoSense is used for the monitoring of CO from internal sources (such as hemolysis, a dangerous condition in which red blood cells degrade rapidly), as well as external sources (such as CO poisoning and smoke inhalation). The initial target market is newborns with jaundice that are at risk for hemolysis, comprising approximately three million births in the U.S. and European Union. The Company’s commercial, neonatology-focused product line also includes innovative pulmonary resuscitation solutions, including the NeoPIP™ Infant T-Piece Resuscitator and Universal T-Piece Circuit consumables. Capnia’s proprietary therapeutic technology uses nasal, non-inhaled CO₂ and is being evaluated to treat the symptoms of allergies, as well as the trigeminally-mediated pain conditions such as cluster headache, trigeminal neuralgia and migraine.

Forward-Looking Statements

This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our sales, ongoing and planned product development, renewed focus on our therapeutic business and the success of this collaboration to support the adoption of CoSense.

We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this presentation. As a result of these factors, we cannot assure you that the forward-looking statements in this presentation will prove to be accurate. Additional factors that could materially affect actual results can be found in Capnia’s Form 10-Q filed with the Securities and Exchange Commission on November 12, 2015, including under the caption titled “Risk Factors.” Capnia expressly disclaims any intent or obligation to update these forward looking statements, except as required by law.

Investor Relations Contact:
Michelle Carroll/Susie Kim
Argot Partners
(212) 600-1902
michelle@argotpartners.com
susan@argotpartners.com

(AEZS) Announces Additional Market Purchases of Common Shares

Aeterna Zentaris Inc. (NASDAQ:AEZS; TSX:AEZ) (the “Company”) today disclosed that it was advised by certain members of its executive management team that such executives made on-market purchases of an aggregate of 29,535 of the Company’s Common Shares last week at then market prices, representing a total investment by such executives of approximately $90,000. David A. Dodd, Chairman, President and Chief Executive Officer, purchased 16,300 Common Shares for a total investment of approximately $50,000; Jude Dinges, Senior Vice President and Chief Commercial Officer, purchased 6,500 Common Shares for a total investment of approximately $20,000; and Philip A. Theodore, Senior Vice President, Chief Administrative Officer and General Counsel, purchased 6,735 Common Shares for a total investment of approximately $20,000.

Commenting on his continued confidence in the Company’s business and prospects, Mr. Dodd, speaking in his personal capacity and not as an officer of the Company, stated, “I am personally convinced that our business is strong and improving. The Company has two products in Phase 3 studies and a portfolio of three products that it co-promotes. Aeterna Zentaris expects to complete both Phase 3 studies by the end of 2016 and, if the studies meet their primary endpoints, to file NDAs for both products as rapidly as practicable. The Company has sufficient cash on hand to fund operations through the conclusion of the Phase 3 studies and through first quarter, 2017. During the past few years, the business has been streamlined, eliminating over 50% of headcount in the process. I personally believe that Aeterna Zentaris is now a highly focused and much more efficient company. I and other members of the executive management team believed it important to concretely demonstrate to our fellow shareholders our renewed and continued commitment to and confidence in Aeterna Zentaris by increasing our personal investment in and exposure to the Company’s Common Shares. We believe that Aeterna Zentaris’ outlook is promising and the focus is on continuing to progress on the milestones that are intended to deliver increased value and growth to all shareholders.”

Full details of the additional purchases made by the Company’s officers described above as well as other acquisitions of Common Shares made by the Company’s reporting directors and officers is available on the SEDI (System for Electronic Disclosure by Insiders) website of the Canadian Securities Administrators at www.SEDI.ca.

About Aeterna Zentaris Inc.

Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women’s health. We are engaged in drug development activities and in the promotion of products for others. We are now conducting Phase 3 studies of two internally developed compounds. The focus of our business development efforts is the acquisition of licenses to products that are relevant to our therapeutic areas of focus. We also intend to license out certain commercial rights of internally developed products to licensees in territories where such out-licensing would enable us to ensure development, registration and launch of our product candidates. Our goal is to become a growth-oriented specialty biopharmaceutical company by pursuing successful development and commercialization of our product portfolio, achieving successful commercial presence and growth, while consistently delivering value to our shareholders, employees and the medical providers and patients who will benefit from our products. For more information, visit www.aezsinc.com.

Aeterna Zentaris Inc.
Philip A. Theodore, 843-900-3223
Senior Vice President
ir@aezsinc.com

(RLYP) Announces Results From Veltassa Drug-Drug Interaction Studies

• Relypsa reports results from Phase 1 in vivo studies in healthy volunteers evaluating potential drug-drug interactions between Veltassa and 12 drugs administered either at the same time or three hours apart
• The 12 drugs were selected based on results of previously announced in vitro tests, in which Veltassa had demonstrated binding with 14 of 28 drugs tested; 12 of these 14 were considered relevant for further testing to assess whether the in vitro results translated into an effect in people
• Results of the Phase 1 studies showed nine of the 12 drugs tested showed no clinically meaningful reduction in absorption when administered at the same time as Veltassa
• No reduction in absorption was observed for any of the 12 drugs tested with a three-hour dosing separation from Veltassa
• Relypsa management will discuss the results further on a conference call/webcast this afternoon, Monday, January 25, 2016, at 5:30 p.m. ET/2:30 p.m. PT

REDWOOD CITY, Calif., Jan. 25, 2016  — Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced results from 12 Phase 1 studies in healthy volunteers evaluating potential drug-drug interactions between Veltassa^® (patiromer) for oral suspension and 12 drugs that had previously demonstrated binding in in vitro tests. When Veltassa was administered at the same time as the drugs being tested, there was no clinically meaningful reduction in absorption for nine of the 12 drugs. Three drugs showed reduced absorption when they were co-administered with Veltassa, however, when dosing of Veltassa and these drugs was separated by three hours, no reduction in absorption was observed.

“The results from these studies are encouraging as, of the 12 drugs that had previously shown in vitro binding to Veltassa, nine showed no clinically meaningful reduction in absorption when co-administered with Veltassa in people,” said Lance Berman, M.D., chief medical officer of Relypsa. “In addition, when dosing was separated by three hours, there was no impact to absorption of the three drugs that had demonstrated reduced absorption when they were given with Veltassa. We look forward to discussing these data with the FDA and determining next steps.”

Summary of Veltassa Drug-Drug Interaction Program and Results
Veltassa was approved by the U.S. Food and Drug Administration (FDA) on October 21, 2015, for the treatment of hyperkalemia, becoming the first new medicine in more than 50 years for people with elevated blood potassium levels.

The drug-drug interaction program submitted as part of Veltassa’s New Drug Application (NDA) included in vitro drug-drug interaction tests (conducted in test tubes).

As previously announced, in these initial in vitro tests, 14 of the 28 drugs showed no binding with Veltassa, including:

• Antihypertensive medicines (renin angiotensin aldosterone system, or RAAS, inhibitors) – lisinopril, spironolactone, valsartan
• Cholesterol-lowering medicine – atorvastatin
• Anticoagulant and antiplatelet medicines – apixaban, aspirin, rivaroxaban
• Cardiac glycoside – digoxin
• Antidiabetic medicine – glipizide
• Antigout medicine – allopurinol
• Antibiotics – amoxicillin, cephalexin
• Antiepileptic – phenytoin
• Vitamin – riboflavin

Fourteen drugs did show binding in vitro and, of these, 12 were selected for further testing in healthy volunteer studies to assess whether the results seen in vitro translated into an effect in people. These randomized, open-label studies were initiated in September 2015 and used a three-way cross-over design. They evaluated the absorption of these 12 drugs when either co-administered with Veltassa or when administered three hours apart from Veltassa.  In each study, participants received:

• The test drug alone;
• Veltassa and the test drug administered at the same time; or
• Veltassa administered three hours after the test drug.

For each drug tested, the studies evaluated the concentration in the blood over time (area under the curve or AUC) and the peak blood concentration (C_max).

Results of Phase 1 In Vivo Studies

Conference Call Monday, January 25, 2016, at 5:30 p.m. ET (2:30 p.m. PT)
The Relypsa management team will host a conference call and webcast Monday, January 25, 2016, to further discuss the results of these studies. The conference call may be accessed by phone by calling (866) 410-4428 (domestic) or (704) 908-0287 (international), conference code 38500171. To access the slides and live audio webcast, visit the investor relations section of the Relypsa website at http://investor.relypsa.com. The webcast will be archived for 30 days following the call.

About Veltassa
Veltassa is a potassium binder approved for the treatment of hyperkalemia. Veltassa should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.

Made in powder form consisting of smooth, spherical beads, this new medicine is mixed with water (90 milliliters or three ounces) and taken once-a-day with food. Veltassa is not absorbed and acts within the gastrointestinal tract. It binds to potassium in exchange for calcium, primarily in the colon. The potassium is then excreted from the body through the normal excretion process.

IMPORTANT SAFETY INFORMATION

The Prescribing Information for Veltassa includes a Boxed Warning that Veltassa binds to many other orally administered medications, which could decrease their absorption and reduce their effectiveness. Other oral medications should be administered at least six hours before or six hours after Veltassa. Doctors should choose Veltassa or the other oral medication if adequate dosing separation is not possible.

Contraindications
Veltassa is contraindicated in patients with a history of a hypersensitivity reaction to Veltassa or any of its components.

Worsening of Gastrointestinal Motility  
Use of Veltassa should be avoided in patients with severe constipation, bowel obstruction or impaction, including abnormal post-operative bowel motility disorders, because Veltassa may be ineffective and may worsen gastrointestinal conditions. Patients with a history of bowel obstruction or major gastrointestinal surgery, severe gastrointestinal disorders, or swallowing disorders were not included in clinical studies.

Hypomagnesemia
Veltassa binds to magnesium in the colon, which can lead to hypomagnesemia. In clinical studies, hypomagnesemia was reported as an adverse reaction in 5.3 percent of patients treated with Veltassa. Approximately 9 percent of patients in clinical trials developed hypomagnesemia with a serum magnesium value <1.4 mg/dL. Doctors should monitor serum magnesium and consider magnesium supplementation in patients who develop low serum magnesium levels.

Adverse Reactions
The most common adverse reactions (incidence ≥2 percent) were constipation, hypomagnesemia, diarrhea, nausea, abdominal discomfort and flatulence. Mild to moderate hypersensitivity reactions were reported in 0.3 percent of patients treated with Veltassa and included edema of the lips.

For additional Important Safety Information and Veltassa’s full Prescribing Information, please visit www.relypsa.com/veltassa/prescribing-information.

About Relypsa, Inc.
Relypsa, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of polymeric medicines for patients with conditions that are often overlooked and undertreated and can be addressed in the gastrointestinal tract. The Company’s first medicine, Veltassa^® (patiromer) for oral suspension, was developed based on Relypsa’s rich legacy in polymer science. Veltassa is approved in the United States for the treatment of hyperkalemia. Veltassa has intellectual property protection until 2030 in the United States and 2029 in the European Union. More information is available at www.relypsa.com.

Forward-Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Relypsa, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential significance of the drug-drug interaction results and the plans to discuss the results with the FDA and determine next steps. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development and commercialization process, including regulatory requirements, the timing of Relypsa’s regulatory filings, Relypsa’s substantial dependence on Veltassa, Relypsa’s commercialization plans and efforts and other matters that could affect the availability or commercial potential of Veltassa. Relypsa undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Relypsa in general, see Relypsa’s current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2014, and its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2015.

Contact:
Charlotte Arnold
Vice President, Corporate Communications
650.421.9352
IR@relypsa.com

(JST) Enters Into A Merger Agreement

CARLSTADT, N.J., Jan. 25, 2016  — Jinpan International Limited (Nasdaq: JST), a leading designer, manufacturer, and distributor of cast resin transformers, today announced that it has entered into a definitive Agreement and Plan of Merger (the “Merger Agreement“) with FNOF E&M Investment Limited (“Parent“), a limited liability company incorporated under the laws of the British Virgin Islands, and Silkwings Limited (“Merger Sub“), a limited liability company incorporated under the laws of the British Virgin Islands and a wholly owned subsidiary of Parent, pursuant to which Parent will acquire the Company for US$6.00 per common share of the Company.

Subject to the terms and conditions of the Merger Agreement, at the effective time of the merger (the “Effective Time“), Merger Sub will merge with and into the Company, with the Company continuing as the surviving corporation and becoming a wholly-owned subsidiary of Parent (the “Merger“).  At the Effective Time, each of the Company’s common shares issued and outstanding immediately prior to the Effective Time  will be cancelled in exchange for the right to receive US$6.00 per share in cash and without interest, except for the excluded shares (the “Excluded Shares“), which include (i) common shares (the “Rollover Shares”) beneficially owned by Mr. Zhiyuan Li (“Mr. Li“)  and his affiliates (the “Rollover Shareholders“) , (ii) common shares owned by holders of common shares who have validly exercised and not effectively withdrawn or lost their appraisal rights pursuant to Section 179 of the BVI Companies Act, 2004, as amended (“Dissenting Shares”), and (iii) common shares owned by the Company or any direct or indirect wholly-owned subsidiary of the Company.  Each Excluded Share (other than the Dissenting Shares) issued and outstanding immediately prior to the Effective Time, by virtue of the merger and without any action on the part of its holder, shall be cancelled and shall cease to exist as of the Effective Time, and no consideration shall be delivered with respect thereto.

Each of Forebright Smart Connection Technology Limited (“Forebright“) and Mr. Li have entered into an equity commitment letter with Parent, pursuant to which Forebright and Mr. Li have committed to invest in Parent at or immediately prior to the Effective Time an aggregate cash amount equal to $75,500,000. To support a portion of Mr. Li’s  funding obligations under his equity commitment letter with Parent, Forebright has entered into a debt commitment letter with Mr. Li, pursuant to which Forebright shall provide a facility of US$25,000,000 to Mr. Li.  Forebright New Opportunities Fund L.P. has agreed to provide a guarantee for Forebright’s funding obligations under the relevant equity commitment letter and debt commitment letter as set forth above.  Mr. Li and Forebright New Opportunities Fund L.P. have entered into a limited guarantee in favor of the Company in respect of certain payment obligations of Parent under the Merger Agreement.

Forebright is a special purpose vehicle established by Forebright New Opportunities Fund, a private equity fund managed by Forebright Capital Management Limited (“FCM“).  FCM is owned and run by a group of experienced investment professionals who have already successfully completed several going private transactions involving China-based US-listed issuers in recent years, and the market valuation of these privatized companies exceeded, in aggregate, US$ 450 million.

The Company’s board of directors, acting upon the unanimous recommendation of the special committee (the “Special Committee“) formed by the board of directors, approved the Merger Agreement and the transactions contemplated thereby, including the Merger, and resolved to recommend that the Company’s shareholders vote to authorize and approve the Merger Agreement and the transactions contemplated thereby, including the Merger. The Special Committee, which is comprised solely of independent and disinterested directors of the Company who are unaffiliated with any of Parent, Merger Sub, Mr. Li, Forebright or any of the management members of the Company, negotiated the terms of the Merger Agreement with the assistance of its financial and legal advisors.

The Merger, which is currently expected to close during the first half of 2016, is subject to customary closing conditions, including the approval by an affirmative vote of shareholders representing more than fifty percent (50%) of the outstanding Common Shares of the Company, present and voting in person or by proxy as a single class at a general meeting of the Company’s shareholders duly convened to consider the approval of the Merger Agreement and the transactions contemplated thereby, including the Merger. As of the date of the Merger Agreement, the Rollover Shareholders have agreed under a voting agreement to vote all in favor of the Merger Agreement and consummation of the transactions contemplated thereby, including the Merger.  If completed, the Merger will result in the Company becoming a privately held company and its Common Shares will no longer be listed on NASDAQ Global Select Market.

Duff & Phelps, LLC is serving as independent financial advisor to the Special Committee. Gibson, Dunn & Crutcher LLP is serving as United States legal advisor to the Special Committee. Skadden, Arps, Slate, Meagher & Flom LLP is serving as independent United States legal advisor to Mr. Li, Forebright and Parent.

Additional Information about the Transaction

The Company will furnish to the Securities and Exchange Commission (the “SEC“) a report on Form 6-K regarding the proposed transactions described in this announcement, which will include the Merger Agreement. All parties desiring details regarding the proposed Merger are urged to review these documents, which will be available at the SEC’s website (http://www.sec.gov).

In connection with the proposed Merger, the Company will prepare and mail a proxy statement to its shareholders. In addition, certain participants in the proposed Merger will prepare and mail to the Company’s shareholders a Schedule 13E-3 transaction statement. These documents will be filed with or furnished to the SEC. INVESTORS AND SHAREHOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THESE MATERIALS AND OTHER MATERIALS FILED WITH OR FURNISHED TO THE SEC WHEN THEY BECOME AVAILABLE, AS THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY, THE PROPOSED MERGER AND RELATED MATTERS. In addition to receiving the proxy statement and Schedule 13E-3 transaction statement by mail, shareholders also will be able to obtain these documents, as well as other filings containing information about the Company, the proposed Merger and related matters, without charge, from the SEC’s website (http://www.sec.gov) or at the SEC’s public reference room at 100 F Street, NE, Room 1580, Washington, D.C. 20549. In addition, these documents can be obtained, without charge, by contacting the Company at the following address and/or telephone number:

No Offer or Solicitation

The information in this communication is for informational purposes only and is neither an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy any securities or the solicitation of any vote or approval in any jurisdiction pursuant to or in connection with the proposed transactions or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law.

About Jinpan International Limited

Jinpan International Limited (NASDAQ: JST) designs, manufactures, and markets electrical control and distribution equipment used in demanding industrial applications, utility projects, renewable energy installations, and infrastructure projects.  Major products include cast resin transformers, VPI transformers and reactors, switchgears, and unit substations. Jinpan serves a wide range of customers in China and reaches international markets as a qualified supplier to leading global industrial electrical equipment manufacturers.  Jinpan is one of the largest manufacturers of cast resin transformers in China by production capacity.  Jinpan’s four manufacturing facilities in China are located in the cities of Haikou, Wuhan, Shanghai and Guilin. The Company was founded in 1993.  Its principal executive offices are located in Haikou, Hainan, China and its United States office is based in Carlstadt, New Jersey.  For more information, visit www.jinpaninternational.com.

Safe Harbor Provision

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations and observations and involve known and unknown risks, and uncertainties or other factors not under the Company’s control, which may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations implied by these forward-looking statements. These factors are listed from time-to-time in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 20-F for the period ended December 31, 2014 and our subsequent reports on Form 6-K. Except as required by law, we are not under any obligation, and expressly disclaim any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

(NXTD) Rolls out NFC Enabled Wocket Smart Wallets for 2016

MELBOURNE, Florida, January 25, 2016  —

NXT-ID, Inc. (NASDAQ:NXTD) (“NXT-ID” or the “Company”), a company focused on the growing mobile commerce market, announces that effective January 2016, all Wockets sold will be enabled with NFC (Near Field Communication) payment technology.

As new partnerships with financial institutions are completed, Wocket owners will be notified when they can make NFC payment transactions. This will require a software upgrade through the Wocket app. Gino Pereira, CEO of NXT-ID explains” The next generation Wockets are NFC enabled for payments like Apple Pay or Google Pay. It works as they do when you tap your Wocket to a terminal and it takes your payment. In 2016 we envision several product extensions for Wocket including NFC only Wockets and a new smartcard and app product all at different price points for various customer needs and preferences.”

This technology was previewed at the Consumer Electronics Show (CES) in Las Vegas earlier this month along with a new contactless method of making Wocket payments at unmodified point of sale terminals that normally can only accept magnetic stripe cards.

NXT-ID Director Stanley Washington, who spent 17 years as a senior executive at American Express, commented while attending CES, “This is a very exciting period for NXT-ID. The Company has a technology platform that can make payments by multiple methods to suit consumer preferences in a number of different form factors. This makes the technology appealing to strategic partners from financial institutions to makers of devices that would like to incorporate payment technology.”

According to Zion Research and their new report,  “Mobile Wallet (NFC and Remote Payment) Market: Global Industry Perspective, Comprehensive Analysis and Forecast, 2014 – 2020” , global demand for mobile wallet market was valued at USD 500 billion in 2014 and is expected to reach USD 2,500 billion in 2020, growing at a CAGR of approximately 30% between 2015 and 2020.

Wocket® is the smartest wallet you’ll ever own. Designed to protect your identity and replace your old wallet, simply save your cards into Wocket once and they are immediately secured. You can choose a card from the touch screen and Wocket programs its single, smart card (Wocket Card) or uses its NFC touch to pay technology to match your selection. Your Wocket can be used virtually anywhere that credit cards are accepted today. Wocket can also display a variety of barcodes.

All your credit, debit, loyalty, gift, ID, membership, insurance, medical information, passwords, and virtually any other information can be protected on Wocket®.

About NXT- ID Inc. – Mobile Security for a Mobile World

NXT-ID, Inc.’s innovative MobileBio® solution mitigates consumer risks associated with mobile computing, m-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio® suite of solutions that secure consumers’ mobile platforms led by Wocket®; a next generation smart wallet designed to replace all the cards in your wallet, no smart phone required. http://www.wocketwallet.com/

NXT-ID’ wholly owned subsidiary, 3D-ID LLC, is engaged in biometric identification and has 22 licensed patents in the field of 3D facial recognition http://www.nxt-id.com/, http://3d-id.net/

Product images are available for media at: http://press.nxt-id.com

Forward-Looking Statements for NXT-ID: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company’s business strategy. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company’s ability to implement its long range business plan for various applications of its technology; the Company’s ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company’s technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission.

NXT- ID Inc Contact:
Corporate info: info@nxt-id.com

Media:
D. Van Zant
+1-800-665-0411
press@nxt-id.com

(ENOC) Applauds Decision by the US Supreme Court in FERC v. EPSA

BOSTON, Jan. 25, 2016  — EnerNOC, Inc. (Nasdaq:ENOC), a leading provider of energy intelligence software (EIS), applauds today’s decision by the United States Supreme Court in Federal Energy Regulatory Commission (FERC) v. Electric Power Supply Association. This landmark ruling preserves FERC’s jurisdiction over the participation of demand response in US wholesale electricity markets.

“We are extremely proud of our involvement in this seminal case that ensures an important role for demand-side resources in our nation’s wholesale electricity markets. Today’s decision is a tremendous win for all energy consumers, for the economy, and for the environment. We commend the Court and look forward to continuing to help customers actively participate in our nation’s wholesale markets,” said Tim Healy, Chairman and CEO of EnerNOC.

About EnerNOC

EnerNOC is a leading provider of cloud-based energy intelligence software (EIS) and services to thousands of enterprise customers and utilities globally. EnerNOC’s EIS solutions for enterprise customers improve energy productivity by optimizing how they buy, how much they use, and when they use energy. EIS for enterprise includes budgeting and procurement, utility bill management, facility optimization, visibility and reporting, project tracking, demand management, and demand response. EnerNOC’s EIS solutions for utilities help maximize customer engagement and the value of demand-side resources, including demand response and energy efficiency. EnerNOC supports customer success with its world-class professional services team and a Network Operations Center (NOC) staffed 24x7x365. For more information, visit www.enernoc.com.

Safe Harbor Statement

Statements in this press release regarding management’s future expectations, beliefs, intentions, goals, strategies, plans or prospects, including, without limitation, statements relating to the future growth and success of the Company’s energy intelligence software, and the benefits that customers may derive from technology updates or enhancements to that software, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements can be identified by terminology such as “anticipate,” “believe,” “could,” “could increase the likelihood,” “estimate,” “expect,” “intend,” “is planned,” “may,” “should,” “will,” “will enable,” “would be expected,” “look forward,” “may provide,” “would” or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to under the section “Risk Factors” in EnerNOC’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, as well as other documents that may be filed by EnerNOC from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company’s actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. EnerNOC is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

EnerNOC Media Relations: 
Robin Woodcock
617.692.2601
news@enernoc.com 

EnerNOC Investor Relations:
Christopher Sands
617.692.2569
ir@enernoc.com

(AMDA) Enhances Valeo II™ Product Family w/ 2nd Gen Cervical System

Valeo II C Interbody Further Improves Imaging and Fusion Assessment Capabilities

SALT LAKE CITY, Jan. 25, 2016  — Amedica Corporation (Nasdaq:AMDA), a company that develops and commercializes silicon nitride ceramics as a biomaterial platform, is pleased to announce the release of its Valeo II™ C interbody fusion device system. The second generation cervical system will be commercially available mid-February 2016.

The Valeo II C interbody fusion device, made entirely of Amedica’s micro composite silicon nitride biomaterial, offers a slim-profile design which improves intraoperative visibility for more exact placement and postoperative visibility, providing better assessment of successful fusion.  The new design also includes directional teeth to resist expulsion, an anterior thread connection for improved inserter stability, and a 14x12mm footprint size for smaller patients.  Accompanying the revised implants are new consolidated, single-level instrumentation sets with improved ergonomics and ease of use.

“As I began using the second generation Amedica silicon nitride cervical interbody in my first few cases, it become very evident to me the ease of use this system offers, as well as the clinical benefits my patients were experiencing over allograft,” said Dr. David M. Jones, MD, Piedmont Neurosurgery and Spine, Hickory, NC. “The new innovative design coupled with this unique biomaterial can revolutionize spinal fusion procedures, and ensure a level of inter-operative and post-operative accuracy that is unparalleled today.”

“We are very excited to supplement this innovative product line with an additional second generation interbody offering,” said Dr. Sonny Bal, Chairman and CEO of Amedica Corporation. “Because of silicon nitride’s unique imaging and osteointegration properties and the improved design, surgeons are able to assess fusion more effectively and earlier in the healing process. The feedback received from our limited release has been extremely positive and very encouraging for our vision of the widespread adoption of silicon nitride as the ideal material for spine fusion.”

The Valeo II C interbody fusion device is made of micro composite silicon nitride biomaterial, which offers a favorable environment for bone growth and osteointegration, when compared to competitive PEEK and titanium offerings. Valeo II silicon nitride interbody fusion devices are also semi-radiolucent with clearly visible boundaries in x-rays and produce no artifacts under MRI or CT scans. The combination of these properties is found only in Amedica’s silicon nitride biomaterial technology.

The Valeo C family of products is the first to receive FDA clearance for two-level cervical interbody cage indications. Valeo cervical fusion devices are indicated for use in skeletally mature patients with degenerative disc disease at one disc level or two contiguous levels and are designed for use with autograft or allograft to facilitate fusion. Additional information about Amedica’s complete line of products can be found at www.amedica.com.

About Amedica Corporation
Amedica is focused on the development and application of interbody implants manufactured with medical-grade silicon nitride ceramic. Amedica markets spinal fusion products and is developing a new generation of wear- and corrosion-resistant implant components for hip and knee arthroplasty as well as dental applications. The Company’s products are manufactured in its ISO 13485 certified manufacturing facility and through its partnership with Kyocera, one of the world’s largest ceramic manufacturers. Amedica’s spine products are FDA-cleared, CE-marked, and are currently marketed in the U.S. and select markets in Europe and South America through its distributor network and its growing OEM and private label partnerships.

For more information on Amedica or its silicon nitride material platform, please visit www.amedica.com.

Forward-Looking Statements
This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include, but are not limited to, the intent, belief or current expectations of Amedica and members of its management team with respect to Amedica’s future performance, business operations and acceptance of its technology platform. Statements relating to Amedica’s market opportunities, growth, future products, market acceptance of its products, sales and financial results and similar statements are subject to risks and uncertainties such as the timing and success of new product introductions, physician acceptance, endorsement, and use of Amedica’s products, regulatory matters, competitor activities, changes in and adoption of reimbursement rates, potential product recalls, effects of global economic conditions and changes in foreign currency exchange rates. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found in Amedica’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 24, 2015, and in Amedica’s other filings with the SEC. Amedica disclaims any obligation to update any forward-looking statements.

Mike Houston
VP, Commercialization 
801-839-3534
IR@amedica.com

Robert Haag
IRTH Communications
866-976-4784
amda@irthcommunications.com

(QUIK) CTO to Present at Telit DevCon IoT Innovation Conference

(ADAP) Announces New Additions to Manufacturing Senior Management

PHILADELPHIA and OXFORD, United Kingdom, Jan. 22, 2016  — Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that it has augmented its manufacturing leadership to prepare for clinical and commercial scale up with the additions of William Buecheler as Vice President, Manufacturing Operations, and Phil Bassett as Head of Process Development.

Mr. Buecheler is responsible for Adaptimmune’s global manufacturing operations, including contract and in-house manufacturing activities, and is leading the implementation of scale up plans designed to achieve commercial manufacturing capability. Mr. Bassett is responsible for process development activities including leading Adaptimmune’s T-cell and lentivirus process development.

“Adaptimmune is in the midst of scaling up its manufacturing expertise, which significantly enhances our ability to run multiple clinical studies of our TCR therapies and, eventually, commercialize our products,” said James Noble, Chief Executive Officer. “As such, manufacturing excellence is key to our long term success. Hiring the best in the field of manufacturing is critical to us, and Bill and Phil are already making significant contributions.”

Bill Buecheler brings to Adaptimmune over 25 years of industry experience in manufacturing operations, facility planning and expansion, leadership of FDA pre-approval inspection and document preparation, and manufacturing process improvements. He joins Adaptimmune from Novartis Pharmaceuticals, where he acted as the Director and Process Unit Head, with responsibility for overall manufacturing operations of the Cell and Gene Therapy Process Unit. As a member of the senior leadership team, his responsibilities included manufacturing efforts to support the scale up operations for Novartis’ CTL019 chimeric antigen receptor product for treatment of ALL and CLL patients. Prior to joining Novartis, he worked and consulted for numerous pharmaceutical and biotech companies in areas including facility build out and expansion, change control, process improvement, cycle time reduction and critical path project management. Mr. Buecheler earned his Master of Business Administration degree from Syracuse University.

Phil Bassett brings with him over 15 years of process manufacturing experience in CMO, small biotech and large biopharma environments. Most recently, Mr. Bassett served as Head of Manufacturing Development for the Cell Therapy Catapult, a UK-based Center of Excellence in cell therapy, where he was responsible for technology transfer and providing late stage commercial manufacturing, scale-up and process industrialization expertise. Prior to the Cell Therapy Catapult, he served at UCB Celltech as the Associate Director and Head of Fermentation Process Sciences, managing the upstream development team working on clinical and commercial processes, and leading process development, scale up and technology transfer efforts. He also spent several years in roles of increasing responsibility with Cobra Biomanufacturing plc, a UK-based international contract development and manufacturing organization providing biologics for pre-clinical and clinical supply.

About Adaptimmune

Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor (TCR) platform. Established in 2008, the company aims to utilize the body’s own machinery – the T-cell – to target and destroy cancer cells by using engineered, increased affinity TCRs as a means of strengthening natural patient T-cell responses. Adaptimmune’s lead program is an affinity enhanced T-cell therapy targeting the NY-ESO cancer antigen. Its NY-ESO TCR affinity enhanced T-cell therapy has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types, including synovial sarcoma and multiple myeloma. In June 2014, Adaptimmune announced that it had entered into a strategic collaboration and licensing agreement with GlaxoSmithKline (GSK) for the development and commercialization of the NY-ESO TCR program in partnership with GSK. In addition, Adaptimmune has a number of proprietary programs. The company has identified over 30 intracellular target peptides preferentially expressed in cancer cells and is currently progressing 12 through unpartnered research programs. Adaptimmune has over 200 employees and is located in Oxfordshire, U.K. and Philadelphia, USA. For more information: http://www.adaptimmune.com

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 20-F filed with the Securities and Exchange Commission on October 13, 2015. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

Adaptimmune Contacts

Will Roberts
Vice President, Investor Relations
T:  (215) 825-9306  
E: will.roberts@adaptimmune.com

Margaret Henry 
Head of PR 
T: +44 (0)1235 430036 
Mob: +44 (0)7710 304249 
E: margaret.henry@adaptimmune.com

(CGIX) Launches Comprehensive Immuno-Oncology Testing Portfolio

• Immuno-oncology drugs are expected to reach $35 billion in sales by 2024 and potentially impact up to 60% of all cancer patients
• Cancer Genetics, Inc. will offer immuno-oncology marker testing and technologies for both solid tumors and blood based cancers

RUTHERFORD, N.J. and LOS ANGELES, Jan. 21, 2016  — Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), a leader in enabling precision medicine for oncology through molecular markers and diagnostics announced today that it has developed and launched a comprehensive portfolio of tests and technologies to help measure and monitor immuno-oncology markers and select patients for targeted therapies. This portfolio will be available for clinical trials, patient care, and translational research utilizing multiple technological platforms and will be available at CGI’s New Jersey and Los Angeles facilities. In addition, the newly acquired Center of Excellence For Solid Tumor Testing based in Los Angeles, formerly Response Genetics, will also offer the FDA-approved PDL-1 antibody for selection of patients that are most likely to benefit from key immuno-oncology drugs.

Immuno-oncology is a highly promising area of medicine and has already seen several blockbuster therapies enter the market in disease areas such as non-small cell lung cancer and melanoma. Several of these drugs require identification of patients that have a high likelihood of response. As a result, healthcare professionals require identification and potentially companion diagnostics to facilitate patient care.  Clinical trials, targeted therapies that are under development, and many existing approved oncology drugs are undergoing clinical research to identify patient groups that can benefit from stimulating an effective immune response against cancer. The goal is to achieve a more durable or more effective response to the therapy.

Immuno-oncology drugs by themselves have been shown to be highly effective in 20 to 30 percent of patients, and combination therapies are bringing the promise of more significant patient benefits.  In order to develop more effective treatments with fewer side effects, immune-oncology biomarkers and tests helping to assess the effects of therapies will play a key role.

Wall Street analysts are projecting over $35 billion in annual worldwide sales for immuno-oncology drugs by 2024, which would account for half of all spending on cancer drugs, according to market research firm IMS Health. According to pharmaceutical analysts, major pharmaceutical multinational companies are all expected to spend nearly $1 billion a year on immuno-oncology research, early access, and development programs and clinical trials. CGI offers the entire portfolio of immuno-oncology testing and technologies to help pharmaceutical and biotech companies accelerate their clinical trials by integrating immune response data with the genomic and biomarker data that CGI currently provides. This integrated offering will be critical in expanding the CGI value proposition to biotech and pharma companies and increasing the total addressable market for CGI.

“In an era of precision and increasingly personalized therapy, the healthcare industry demands cost-effective options that can robustly identify biomarkers to help select cancer patients most likely to benefit from the emerging class of immuno-oncology drugs,” said Panna Sharma, President and CEO. “CGI has prepared an extensive portfolio of technologies ranging from Immunohistochemistry (IHC) and immuno-phenotyping by flow cytometry to RNA-sequencing. These technologies address the tremendous demand we are experiencing by providing both genomic and immune-marker information to clinical trials and patient care.”

The CGI portfolio of immuno-oncology tests includes immunohistochemistry (IHC)-based tests that can detect novel biomarkers like PD-1 and PD-L1 and flow cytometry-based tests and panels that can assess immune response against cancers by evaluating subsets of immunomodulatory and effector cells. CGI also offers a next generation sequencing (NGS)-based targeted RNA sequencing test that can measure expression levels of drug targets, tumor infiltrate composition, and total immune cell composition. Many of these assays are also available for clinical use and are CLIA- and New York State-approved.

Several drugs targeting PD-1/PD-L1 interactions are currently either FDA approved or in clinical trials. Assessment of PD-L1 expression on tumor cells and in tumor microenvironments is currently used as a biomarker for immunotherapies in patients who fail first-line treatment for non-small cell lung cancer (NSCLC), melanoma, colon cancer, bladder cancer, and hematologic malignancies, among others.

CGI now offers commercial assays for anti-PD-L1 staining and assessment using IHC on formalin-fixed paraffin-embedded (FFPE) tissue for multiple tumor indications, including non-small cell lung cancer (NSCLC), colon adenocarcinoma, melanoma, and several subtypes of non-Hodgkin lymphoma. The in-house expertise of surgical and hemato-pathologists allows reliable evaluation of these markers using complex scoring schemes. Additionally, CGI has capabilities and reporting to integrate genomic and other biomarker data with the immune-marker status to provide a systems approach to measuring and monitoring patients.

CGI will continue expanding the overall capabilities in immuno-oncology and immunotherapy and integrate these capabilities with the genomic and biomarker-based testing being provided in both its New Jersey and Los Angeles centers of excellence.

About Cancer Genetics
Cancer Genetics Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.

The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.

For more information, please visit or follow CGI at:

Internet: http://www.cancergenetics.com
Twitter: @Cancer_Genetics
Facebook: www.facebook.com/CancerGenetics

Forward Looking Statements
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements.

Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Forms 10-K for the year ended December 31, 2014 and 10-Q for the quarter ended September 30, 2015 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.

Media Contact:
Cancer Genetics, Inc.

Marie-Agnes Patrone-Michellod,PhD.

Tel: 201.528.9200

Email: marie.michellod@cgix.com

(HDP) Named a Leader in Big Data Hadoop by Forrester

SANTA CLARA, Calif., Jan. 22, 2016  — Hortonworks, Inc. (NASDAQ: HDP) today announced that it was among the select companies that Forrester Research, Inc. invited to participate in its January 2016 report entitled The Forrester Wave™: Big Data Hadoop Distributions, Q1 2016. In this evaluation, Hortonworks was cited as a Leader and had the highest score in the strategy criterion. According to the Forrester Report, “Enterprise Hadoop is a market that is not even 10 years old, but Forrester estimates that 100% of all large enterprises will adopt it (Hadoop and related technologies such as Spark) for big data analytics within the next two years.”

The Forrester Report noted, “Hortonworks doubles-down on inclusive, broad community innovation. Hortonworks is a rock when it comes to its promise to offer a 100% open source distribution. All of the technology built into HDP is an Apache open source project. Hortonworks will acquire companies to fill enterprise gaps and immediately contributes the code to an Apache project for the good of the community. For example, Hortonworks acquired XA Secure, a company with a commercially licensed security solution, and contributed the code to Apache as Apache Ranger. Hortonworks is also an important member of the Open Data Platform initiative (ODPi) formed earlier this year with IBM, Pivotal Software, and 12 other technology vendors, because the group has adopted Hortonworks-initiated projects such as Apache Ambari. Customers value Hortonworks’ approach to open source innovation.”

Hortonworks Data Platform (HDP™) is the only completely open source Apache™ Hadoop® data platform, architected for the enterprise. With YARN as its architectural center it provides a data platform for multi-workload data processing across an array of processing methods – from batch through interactive to real-time, supported by key capabilities required of an enterprise data platform — spanning Governance, Security and Operations.

“The Big Data and Hadoop markets are changing rapidly thanks to the tremendous amount of work taking place within the Apache community,” said Scott Gnau, chief technology officer, Hortonworks. “We are excited about the opportunity to accelerate the adoption of Open Data Platforms for the enterprise and to continue defining the market for customers.”

About Hortonworks

Hortonworks is the leader in accelerating business transformations with Open Enterprise Hadoop by developing, distributing and supporting an enterprise-scale data platform built entirely on open source technology including Apache™ Hadoop®. Our team comprises the largest contingent of builders and architects within the Hadoop ecosystem who represent and lead the broader enterprise requirements within these communities.

The Hortonworks Data Platform provides an open platform that deeply integrates with existing IT investments and upon which enterprises can build and deploy Hadoop-based applications. Hortonworks has deep relationships with the key strategic data center partners that enable our customers to unlock the broadest opportunities from Hadoop.

For more information, visit www.hortonworks.com. Join us at the Apache Hadoop 10 year anniversary party, held at Hadoop Summit Europe and North America in 2016.

Hortonworks, HDP and HDF are registered trademarks or trademarks of Hortonworks, Inc. and its subsidiaries in the United States and other jurisdictions.

Media contact:
Erin Smith
510.928.4454
comms@hortonworks.com

(HNSN) Announces Exploration of Strategic Alternatives

(GLNG) and Schlumberger sign Memorandum of Understanding

Golar LNG today announced that it has signed a Memorandum of Understanding with Schlumberger to co-operate on the global development of greenfield, brownfield and stranded gas reserves.

Under the Memorandum, Golar and Schlumberger have agreed to jointly market gas monetization solutions to owners, investors and governments. Golar will contribute the Floating LNG assets and technology while Schlumberger, via its special project management division, will provide upstream development knowledge, resources and capital.  The intention of this integrated offer is to gain access to a wide range of uneconomic gas reserves by delivering low-cost LNG production solutions.

This is a ground breaking agreement that will provide resource holders with a completely integrated package both reducing risk and securing financing for gas projects. The main aim of the venture is to accelerated the time it takes to bring proven gas reserves into production.

Both parties have initiated their activities and have already made solid progress expecting to announce the first project within the next two months.

FORWARD LOOKING STATEMENTS

This press release contains certain forward-looking statements concerning future events and Golar’s operations, performance and financial condition. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain the words “believe”, “anticipate”, “expect”, “estimate”, “project”, “will be”, “will continue”, “will likely result”, “plan”, “intend” or words or phrases of similar meanings. These statements involve known and unknown risks and are based upon a number of assumptions and estimates that are inherently subject to significant uncertainties and contingencies, many of which are beyond Golar’s control. Actual results may differ materially from those expressed or implied by such forward-looking statements.

Golar LNG Limited
Hamilton, Bermuda
22 January, 2016

(MMLP) Partners Announces Quarterly Cash Distribution, Q4 Results

KILGORE, Texas, Jan. 21, 2016  — Martin Midstream Partners L.P. (NASDAQ:MMLP) announced today it has declared a quarterly cash distribution of $0.8125 per unit, or $3.25 per unit on an annualized basis, for the quarter ended December 31, 2015.  The quarterly distribution is unchanged from the distribution paid following the previous quarter.  The distribution is payable on February 12, 2016 to common unitholders of record as of the close of business on February 5, 2016.  The ex-dividend date for the cash distribution is February 3, 2016.

Martin Midstream Partners plans to publicly release its financial results for the fourth quarter ended December 31, 2015 after the market closes on Wednesday, February 24, 2016.  An investors conference call to review the fourth quarter results will be held on Thursday, February 25, 2016 at 8:00 a.m. Central Time. The conference call can be accessed by calling (877) 878-2695.  An audio replay of the conference call will be available by calling (855) 859-2056 from 11:00 a.m. Central Time on February 25, 2016 through 10:59 p.m. Central Time on March 8, 2016.  The access code for the conference call and the audio replay is Conference ID No. 34231812. The audio replay of the conference call will also be archived on Martin Midstream Partners’ website at www.martinmidstream.com.

During the conference call, management will discuss certain non-generally accepted accounting principle financial measures for which reconciliations to the most directly comparable GAAP financial measures will be provided in Martin Midstream Partners’ announcement concerning its financial results for the quarter ended December 31, 2015 which will be available on the investor relations page of Martin Midstream Partners’ website.

Qualified Notice to Nominees

This release serves as qualified notice to nominees as provided for under Treasury Regulation Section 1.1446-4(b)(4) and (d). Please note that 100 percent of the Partnership’s distributions to foreign investors are attributable to income that is effectively connected with a United States trade or business. Accordingly, all of the Partnership’s distributions to foreign investors are subject to federal income tax withholding at the highest effective tax rate for individuals or corporations, as applicable. Nominees, and not the Partnership, are treated as withholding agents responsible for withholding on the distributions received by them on behalf of foreign investors.

About Martin Midstream Partners

Martin Midstream Partners L.P. is a publicly traded limited partnership with a diverse set of operations focused primarily in the United States Gulf Coast region.  The Partnership’s primary business lines include: (1) terminalling, storage and packaging services for petroleum products and by-products; (2) natural gas liquids transportation and distribution services and natural gas storage; (3) sulfur and sulfur-based products processing, manufacturing, marketing and distribution; and (4) marine transportation services for petroleum products and by-products.

Forward-Looking Statements

Statements about Martin Midstream Partners’ outlook and all other statements in this release other than historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements and all references to financial estimates rely on a number of assumptions concerning future events and are subject to a number of uncertainties and other factors, many of which are outside its control, which could cause actual results to differ materially from such statements. While Martin Midstream Partners believes that the assumptions concerning future events are reasonable, it cautions that there are inherent difficulties in anticipating or predicting certain important factors. A discussion of these factors, including risks and uncertainties, is set forth in Martin Midstream Partners’ annual and quarterly reports filed from time to time with the Securities and Exchange Commission. Martin Midstream Partners disclaims any intention or obligation to revise any forward-looking statements, including financial estimates, whether as a result of new information, future events, or otherwise.

Additional information concerning Martin Midstream is available on its website at www.martinmidstream.com, or

Joe McCreery – Head of Investor Relations
(903) 988-6425

(AGEN) Announces Clearance of IND Apps for anti-CTLA-4 and anti-GITR Antibodies

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing checkpoint modulator antibodies and cancer vaccines, announced today that the U.S. Food and Drug Administration (FDA) cleared the company’s investigational new drug (IND) application for AGEN1884, an immune checkpoint modulator (CPM) antibody that binds to cytotoxic T-lymphocyte antigen-4 (CTLA-4). Clearance was also received for a second CPM antibody partnered with Incyte (NASDAQ: INCY) for INCAGN1876, which targets glucocorticoid-induced TNFR-related protein (GITR). Clinical trials for both candidates are expected to begin in the first half of 2016.

“We are pleased with the prospects of both CTLA-4 and GITR moving rapidly into and through the clinic, and in our efforts to bring profoundly effective medicines to cancer patients,” said Garo Armen, PhD, Chairman and CEO of Agenus. “We are also diligently advancing several other product candidates into the clinic and are aiming to begin a number of clinical trials in 2016.”

These two compounds were developed utilizing Agenus’ state-of-the-art monoclonal antibody platform capabilities and leverage the company’s world-class expertise in immuno-oncology and related drug discovery and development. The antibodies were discovered during an earlier collaboration with Ludwig Cancer Research. Recepta, a Brazilian biotech company, was also involved in the collaboration that led to the discovery of AGEN1884, which is partnered with Recepta for certain South American rights. INCAGN1876 is now being co-developed with Incyte.

“CTLA-4 is emerging as an important foundational target for immuno-oncology combination regimens, showing terrific promise when used with other CPMs and cancer vaccines. Our CTLA-4 antagonist antibody, AGEN1884, is a natural potential fit with our expanding vaccine portfolio. This includes Prophage™, slated to enter a randomized placebo-controlled study in newly diagnosed GBM in the second half of 2016, and AutoSynVax™, which we also plan to take into the clinic in the second half of 2016,” said Robert B. Stein, MD, PhD, Agenus’ President, Research & Development. “I would like to acknowledge the research and development teams at Agenus, and Incyte for GITR, for their tireless efforts to achieve our goal of filing these INDs by the end of 2015.”

About Checkpoint Modulators

Promising clinical data from studies employing monoclonal antibodies that bind to checkpoint molecules, such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death receptor-1 (PD-1), have generated considerable excitement in the field of cancer immunotherapy. These molecules serve as checks employed by the body to prevent a runaway immune response, which can be debilitating, and even deadly. Unfortunately, these necessary mechanisms of control can hinder the anti-cancer immune response. They can be harnessed by cancer cells as a defense against immune attack. Agenus is developing a broad pipeline of antibodies that bind to key checkpoint proteins and activate or block their activities for use in cancer therapy.

About Agenus

Agenus is an immunotherapy company focused on the discovery and development of revolutionary new treatments that engage the body’s immune system to benefit patients suffering from cancer. By combining multiple powerful platforms, Agenus has established a highly integrated approach to target identification and validation, and for the discovery, development and manufacturing of monoclonal antibodies that modulate targets of interest. The company’s broad portfolio of novel checkpoint modulator and other immuno-modulatory monoclonal antibodies, vaccines and adjuvants, work in combination to provide the opportunity to create best-in-class therapeutic regimens. Agenus’ heat shock protein-based vaccine, Prophage™, has successfully completed Phase 2 studies in newly-diagnosed glioblastoma. The company is collaborating with Merck and Incyte to discover and develop multiple checkpoint modulators. For more information, please visit www.agenusbio.com; information that may be important to investors will be routinely posted on our website.

Forward-Looking Statement

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding planned clinical trial activities of Agenus and its partners, as well as the efficacy of certain product candidates. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of Agenus’ Form 10-Q filed with the Securities and Exchange Commission on November 4, 2015. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Agenus:
Agenus Inc.
Michelle Linn, 774-696-3803
michelle.linn@agenusbio.com
or
Media:
BMC Communications
Brad Miles, 646-513-3125
bmiles@bmccommunications.com

(CPST) Receives Additional Follow-on Order for Australian Coal Seam Gas Company

CHATSWORTH, Calif., Jan. 21, 2016  — Capstone Turbine Corporation (www.capstoneturbine.com) (Nasdaq:CPST), the world’s leading clean technology manufacturer of microturbine energy systems, announced today that it received an additional follow-on order for a large Australian coal seam gas company.

The initial order in July 2008 was for the supply of 112 C30 microturbines, which was later increased to 154 C30s in 2009. The first follow-on contract was for 44 C30 microturbines in September 2012, and in January 2013 they ordered 36 additional units, followed by another 14 units in December 2013. This latest order is for another 8 units, bringing the total number of microturbines sold to date to 256. These orders are part of a periodical supply contract for the life of the coal seam development project.

“The coal seam gas market continues to develop as coal seam operators convert this gas into clean on-site power generation,” said Darren Jamison, Capstone’s President and Chief Executive Officer. “It’s rewarding to see satisfied repeat customers continue to come back and add to their already large fleets of operating microturbines. In addition, Australia has been a key geographical focus for Capstone, similar to Latin America, Africa and the Middle East,” added Mr. Jamison.

Optimal Group, Capstone’s Australian distributor, secured the latest follow-on order, which is currently scheduled to be commissioned in mid-2016. In Australia, coal seam gas is plentiful. Coal seam gas has been known about ever since the coal mining industry began in Australia in the early 1900s. With advances in technology, it has developed into a key transition fuel, helping to lower Australia’s carbon emissions as the country moves to a lower carbon future.

“Optimal Group’s business in Australia continues to expand in oil and gas, coal seam gas and the combined heat and power markets. In fact, they are currently our second largest distributor in terms of revenue generation over the trailing four quarters,” said Jim Crouse, Capstone’s Executive Vice President of Sales and Marketing. “I am confident that Australia will deliver substantial growth year-over-year and help offset slowdowns in other geographies,” added Mr. Crouse.

About Capstone Turbine Corporation

Capstone Turbine Corporation (www.capstoneturbine.com) (Nasdaq:CPST) is the world’s leading producer of low-emission microturbine systems and was the first to market commercially viable microturbine energy products. Capstone Turbine has shipped over 8,600 Capstone Microturbine systems to customers worldwide. These award-winning systems have logged millions of documented runtime operating hours. Capstone Turbine is a member of the U.S. Environmental Protection Agency’s Combined Heat and Power Partnership, which is committed to improving the efficiency of the nation’s energy infrastructure and reducing emissions of pollutants and greenhouse gases. A UL-Certified ISO 9001:2008 and ISO 14001:2004 certified company, Capstone is headquartered in the Los Angeles area with sales and/or service centers in the New York Metro Area, United Kingdom, Mexico City, Shanghai and Singapore.

The Capstone Turbine Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6212

This press release contains “forward-looking statements,” as that term is used in the federal securities laws, about the advantages of our products and the growth of the coal seam gas market. Forward-looking statements may be identified by words such as “expects,” “objective,” “intend,” “targeted,” “plan” and similar phrases. These forward-looking statements are subject to numerous assumptions, risks and uncertainties described in Capstone’s filings with the Securities and Exchange Commission that may cause Capstone’s actual results to be materially different from any future results expressed or implied in such statements. Capstone cautions readers not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Capstone undertakes no obligation, and specifically disclaims any obligation, to release any revisions to any forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

“Capstone” and “Capstone MicroTurbine” are registered trademarks of Capstone Turbine Corporation. All other trademarks mentioned are the property of their respective owners.

CONTACT: 
Capstone Turbine Corporation
Investor and investment media inquiries:
818-407-3628
ir@capstoneturbine.com

INVESTORS:
Dian Griesel Int’l
Cheryl Schneider/Tom Caden
212-825-3210

(UPIP) Wins German Cellular Essential Patent Infringement Case Against Samsung

Unwired Planet, Inc. (NASDAQ:UPIP) today announced that the Düsseldorf District Court in Germany issued its judgments that cell phone and infrastructure manufacturers Samsung, LG Electronics and Huawei each infringe multiple Unwired Planet patents. The judgments come after an initial trial held in June 2015 against Huawei, and a multi-day trial held in late November and December 2015 against the other defendants.

Confirmation of Infringement

The Düsseldorf District Court court held that the defendants’ LTE and GSM compliant handsets infringe three Unwired Planet patents: EP (DE) 2,119,287 and EP (DE) 2,485,514, and EP (DE) 1 230 818. With respect to infrastructure equipment, the court found that Samsung and Huawei’s infrastructure equipment infringes patent EP (DE) 2,119,287 but not patent EP (DE) 2,485,514.

The defendants filed actions with the German Federal Patent Court alleging that the patents are invalid; however, the Düsseldorf court did not grant a stay of the proceedings. The court ruled that it did not find a sufficient likelihood that these actions, called “nullity actions” in Germany, would be successful. In the German case, claimant Unwired Planet International Ltd. was represented by Ben Grzimek of the EIP Law Firm and Hosea Haag of the Ampersand firm.

“This is a great result and certainly increases our chances of being fairly and properly compensated,” said Unwired Planet CEO Boris Teksler. “This judgment marks one of the few decisions in Europe after the landmark Huawei v. ZTE decision last July governing the conduct of FRAND licensing. This decision solidifies wins in two jurisdictions and increases the number of cellular standard essential patents to four that have been positively adjudicated by the courts.”

On July 16, 2015, the Court of Justice of the European Union (CJEU), the highest appellate court in the European Union, provided needed guidance regarding the obligations of both patent holders who want to assert their standard essential patents and the alleged infringers who wants to rely on the FRAND license defense (Huawei v ZTE, 16 July 2015, Case C-170/13).

“The CJEU set out the general principles for both licensors and licensees. To date we’ve only sought monetary damages for the defendants’ infringement,” said Unwired Planet general counsel Noah D. Mesel. “The CJEU’s licensing principles specify that patent holders may seek injunctive relief in certain circumstances if the infringer fails to negotiate in good faith with the patent holder on the terms of a license.”

UK Litigation Update

As is widely known, the UK courts employ a “loser-pays” fee-shifting system. On December 16, 2015, the Court ordered Samsung and Huawei to make an initial partial payment of £1,270,800 (approximately $1.9 million) on account of Unwired Planet’s legal fees for the first UK trial. Those payments now have been made. If the parties do not agree on a total fee amount due to Unwired Planet, a further hearing will be calendared.

On a related note Samsung and Huawei have filed an appeal of the UK High Court’s decision of the findings of validity and infringement of the EP (UK) 2 229 744 patent. The court has not set a briefing or hearing schedule on that appeal.

Unwired Planet concluded a second trial in the UK in mid-December and expects to receive a ruling from the UK High Court before the end of January 2016 on EP (UK) 2,119,287 and EP (UK) 2,485,514.

About Unwired Planet, Inc.

Unwired Planet, Inc. (NASDAQ:UPIP) is the inventor of the Mobile Internet and a premier intellectual property company focused exclusively on the mobile industry. The company’s patent portfolio of approximately 2,500 issued and pending US and foreign patents, includes technologies that allow mobile devices to connect to the Internet and enable mobile communications. The portfolio spans 2G, 3G, and 4G technologies, as well as cloud-based mobile applications and services. Unwired Planet’s portfolio includes patents related to key mobile technologies, including baseband mobile communications, mobile browsers, mobile advertising, push notification technology, maps and location based services, mobile application stores, social networking, mobile gaming, and mobile search. Unwired Planet is headquartered in Los Altos, California. References in this release to Unwired Planet may be to Unwired Planet, Inc. or its subsidiaries.

The Blueshirt Group
Lauren Sloane, 415-217-2632
Lauren@blueshirtgroup.com

(TROV) Agreement with America’s Choice Provider Network

Agreement provides in-network coverage for 22 million individuals

SAN DIEGO, Jan. 21, 2016  — Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it has entered into an agreement with America’s Choice Provider Network (ACPN®) establishing health insurance access to its entire suite of circulating tumor (ct)DNA Precision Cancer Monitoring℠ (PCM) tests and services. Under the terms of the agreement, Trovagene is established as a preferred provider, and its PCM testing services will be covered by over 1,700 payers in North America.

“We are very much looking forward to having a provider as progressive and innovative as Trovagene in our national provider network,” said Seth Breeden, chief operating officer of ACPN. “It is with great excitement that we can now offer our members access to Trovagene’s Precision Cancer Monitoring services.”

“We are pleased that ACPN has agreed to provide coverage for Trovagene’s PCM full offering of ctDNA products,” said Matt Posard, chief commercial officer of Trovagene. “Our commercial plan is on track to provide national sales coverage, and ACPN is the first of several additional contracts expected this year. In support of our commercialization program, we are creating a strong foundation of data from our clinical studies and manuscript publications demonstrating the medically actionable use of Trovagene’s liquid biopsy platform in the treatment of cancer.”

About America’s Choice Provider Network

Founded in 2012, ACPN is an independent, multispecialty national provider network. Through its proprietary network and technology, ACPN offers access to providers, payers and patients in all 50 States, Canada, the Dominican Republic, Guam, Mexico, and Puerto Rico. ACPN’s products include Individual and Group Health, Workers Compensation, Auto Liability, and Medicare Advantage. Its client base consists of Insurance Carriers, Third Party Administrators, Health and Welfare Funds, Self-Administered Employer Groups, Student Plans, Travel Plans, etc. ACPN’s mission is to achieve consistency in healthcare transactions, simplify claims adjudication processes, create reasonable reimbursement arrangements, and establish reliable healthcare access for all parties—providers, payers and patients.

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is leveraging its proprietary technology for the detection and monitoring of cell-free DNA in urine. The Company’s technology detects and quantitates oncogene mutations in cancer patients for improved disease management. Trovagene’s precision cancer monitoring platform is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property including multiple issued patents and pending patent applications globally.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend,” among others. These forward-looking statements are based on Trovagene’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition;  our need for additional financing; uncertainties of patent protection and litigation; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.  Investors should read the risk factors set forth in Trovagene’s Form 10-K for the year ended December 31, 2014 and other periodic reports filed with the Securities and Exchange Commission.

(SYNA) Unveils Tiny Footprint, Low Power Touch Controller for Small Screens

New S1423 Ideal for Smartwatches, Emerging Wearables, Diverse Touchscreens

SAN JOSE, Calif., Jan. 20, 2016  — Synaptics Incorporated (NASDAQ: SYNA), the leading developer of human interface solutions, today announced sampling of S1423, its newest ClearPad^® touch controller solution for wearables and small screen applications including smartwatches, fitness trackers, and touch enabled appliances such as printers. Supporting round and rectangular shapes, as well as thick and curved lenses, the S1423 offers excellent performance with moisture on screen, while wearing gloves, and supports swipes and gestures including the Android Wear ‘home’ gesture.

Fully optimized and redesigned from the ground up for wearables, the new Synaptics S1423 supports a low-cost single layer sensor design and enables narrow borders. Synaptics’ unique Advanced Matrix Pad (AMP) technology enables industry leading touch accuracy and sensitivity. With less than 6mW active power, the S1423 is highly optimized for small screen wearables where low power is of critical importance.

Synaptics’ first generation wearables solution, the S1222, is in full production and found in many of today’s shipping smartwatches. Beyond wrist wearables, early smart glasses innovators chose Synaptics’ touch solution, while OEMs developing new smart eyewear products are choosing the S1423 due to its improved performance and lower power.

“The user experience is critical with very small screen applications, and we purpose-built these solutions specifically for the wearables market,” said Tim Vehling, vice president, Smart Displays Division, Synaptics. “Our human interface expertise provides unique and proven results. The S1423, with very low power, advanced touch capabilities, and small form factor address this market perfectly.”

About Synaptics:
Synaptics is the pioneer and leader of the human interface revolution, bringing innovative and intuitive user experiences to intelligent devices. Synaptics’ broad portfolio of touch, display, and biometrics products is built on the company’s rich R&D, extensive IP and dependable supply chain capabilities. With solutions designed for mobile, PC and automotive industries, Synaptics combines ease of use, functionality and aesthetics to enable products that help make our digital lives more productive, secure and enjoyable. (NASDAQ: SYNA) www.synaptics.com.

Follow Synaptics on Twitter and LinkedIn, or visit synaptics.com.

Synaptics, ClearPad, and the Synaptics logo are trademarks of Synaptics in the United States and/or other countries. All other marks are the property of their respective owners.

For further information, please contact:
David Hurd, Synaptics, Incorporated
+1-408-904-2766
david.hurd@synaptics.com

Public Relations:
Text 100 Global Communications
Marcelo Vilela
+1-415-593-8419
synaptics@text100.com

(APHB) Announces Dosing of First Patient in Phase 1 Clinical Trial of AB-SA01

AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announces it has dosed the first patient in its Phase 1 clinical trial of AB-SA01 for the treatment of Staphylococcus aureus (S. aureus) infections in patients with chronic rhinosinusitis (CRS) that fail to respond to standard antibiotic treatment.

“This is a key step in the development of a novel therapy to treat an extremely under-served population that exacts a significant financial toll on the healthcare system and the economy,” said M. Scott Salka, CEO of AmpliPhi Biosciences. “Each year, nearly 13 percent of the U.S. population suffers from CRS, resulting in a productivity loss of over $10,000 per person, for a total annual loss in the United States of more than $350 billion. Our goal is to develop a better treatment for this common condition in order to alleviate tremendous suffering, especially in the estimated 2.6 million CRS patients who fail to respond to standard antibiotic treatment and resort to endoscopic surgery, yet continue to be plagued by the disease.”

AmpliPhi’s Phase 1 clinical trial is enrolling patients with CRS – defined as serious, often debilitating infection and inflammation of the nose and sinuses lasting 12 weeks or more – who have not responded to surgery and are infected with S. aureus. AmpliPhi expects to complete enrollment of the trial by the end of the first half of 2016.

“We are confident in our bacteriophage-based approach to treating infection in CRS patients, and we are grateful to our partners at University of Adelaide’s Queen Elizabeth Hospital and Flinders University for their dedication and commitment to moving this important research forward,” continued Mr. Salka.

For more information, visit www.ampliphibio.com.

About AmpliPhi Biosciences

AmpliPhi Biosciences Corporation (NYSEMKT:APHB) is a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics. AmpliPhi’s product development programs target infections that are often resistant to existing antibiotic treatments. AmpliPhi is collaborating with a number of leading organizations, including Intrexon Corporation (NYSE:XON), the U.S. Army, The Royal Brompton Hospital in London, UK and UK-based University of Leicester, to advance bacteriophage-based therapies.

About Bacteriophage

Bacteriophage are naturally occurring viruses that are highly specific for the bacterial hosts they infect. They can rapidly kill their host, amplifying themselves in the process. Bacteriophage are unaffected by antibiotic resistance and are able to disrupt bacterial biofilms. Such biofilms are a major line of defense for bacteria, contributing to antibiotic resistance. Bacteriophage are able to penetrate biofilms and replicate locally to high levels, to produce strong local therapeutic effects.

Forward Looking Statements

Statements in this press release that are not statements of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, without limitation, statements about the expected timing to complete enrollment of patients in AmpliPhi’s Phase 1 clinical trial of AB-SA01 for the treatment of S. aureus, the potential use of bacteriophages to treat bacterial infections, including infections that do not respond to antibiotics, and AmpliPhi’s development of bacteriophage-based therapies. Words such as “believe,” “anticipate,” “plan,” “expect,” “intend,” “will,” “may,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon AmpliPhi’s current expectations and involve a number of risks and uncertainties, including the risks and uncertainties described in AmpliPhi’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, as filed with the Securities and Exchange Commission. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and AmpliPhi undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

Company and Investor relations:
AmpliPhi Biosciences
Matt Dansey
+1 858-800-4869
md@ampliphibio.com
or
Media relations (USA)
Lazar Partners
Danielle Lewis/Glenn Silver
+ 1 212-867-1762
ampliphi@lazarpartners.com
or
Media Relations (Europe and ROW)
Instinctif Partners
Gemma Howe/Sue Charles
+44 (0)20 7866 7905
ampliphi@instinctif.com

(OPTT) APB350 (A1) PowerBuoy Achieves Significant Performance Milestones

PENNINGTON, N.J., Jan. 20, 2016  — Ocean Power Technologies, Inc. (Nasdaq:OPTT) today announced that its APB350 (A1) PowerBuoy^® has achieved several significant milestones.  Total cumulative deployment time has exceeded 125 days and energy generated has surpassed 1,000 kWh (1MWh).  In addition, a new maximum generation record of 32 kWh of energy for a 24-hour period was achieved.  The APB350 A1, deployed off of the coast of New Jersey, has communicated key performance as well as meteorological data from the buoy’s integrated weather station.

George H. Kirby, President and Chief Executive Officer of OPT, stated, “We continue to be very excited by the A1’s overall performance, specifically its power generation in extreme ocean conditions.  The A1 results are significant as it continues to confirm design robustness and demonstrates measurable progress toward commercial readiness on three key focus areas: the PTO; the survivability of the PowerBuoy system during high sea states; and the linear seal, which prevents water from entering the buoy.”

Dr. Mike M. Mekhiche, OPT’s Vice President of Engineering, stated, “In addition, the A1 has provided critical design, performance, and in-ocean operating data.  The new 24-hour energy record is 3.8 times its nameplate daily rating of 8.4 kWh, which is a 14% improvement over the previously reported record.”

Dr. Mekhiche continued, “The A1 also demonstrated its ability to generate sufficient power at very low sea states, which is further confirmation of the PTO efficiency improvements as compared to the original design.  These improvements expand the buoy’s mission persistence and endurance capabilities in terms of providing required power to its payload over longer “zero wave” periods.  This persistence is critical for a variety of autonomous offshore power markets of interest.”

OPT also announced that it will retrieve the A1 for necessary inspection, repairs and maintenance.  The PowerBuoy has been deployed since October, and it will be redeployed at the earliest available weather window.  Upon redeployment, sea trials of the A1 will continue off the coast of New Jersey to further validate the buoy reliability and survivability with periodic inspections as needed.

Dr. Mekhiche stated, “Further progress was also made on the ALT testing, which continues to validate the PTO design and generate important data on its reliability and life.  The ALT process consists of operating PTOs in tandem with accelerated operating profiles, which subjects the PTOs to various load conditions encountered in extreme sea states.  The objective of the test is to simulate an equivalent three-year ocean deployment during a period of approximately nine months using PTOs that are identical to those of the A1.  The ball screw PTO has traveled the equivalent of approximately 1,200 km so far, corresponding to approximately 1.8 million strokes, without any mission critical issues.  The PTO ALT, which is currently operating 24/7, has already exceeded the deployed A1 PTO in terms of strokes and total distance traveled by the PTO.

Mr. Kirby concluded, “We continue to believe that the combination of sea trials, ALT, and feedback from the Technical Advisory Panel are helping us shorten our product’s validation and market introduction time.  We are receiving significant commercial interest resulting from the positive sea trials and ALT results, which supports our goal of 2016 commercialization.”

About Ocean Power Technologies

Headquartered in Pennington, New Jersey, Ocean Power Technologies (Nasdaq:OPTT) is a pioneer in renewable wave-energy technology that converts ocean wave energy into electricity. OPT’s proprietary PowerBuoy^® technology is based on a modular design and has undergone periodic ocean testing since 1997. OPT specializes in cost-effective and environmentally sound ocean wave based power generation and management technology.

Forward-Looking Statements

This release may contain “forward-looking statements” that are within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by certain words or phrases such as “may”, “will”, “aim”, “will likely result”, “believe”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, “project”, “should”, “will pursue” and similar expressions or variations of such expressions. These forward-looking statements reflect the Company’s current expectations about its future plans and performance. These forward-looking statements rely on a number of assumptions and estimates which could be inaccurate and which are subject to risks and uncertainties. Actual results could vary materially from those anticipated or expressed in any forward-looking statement made by the Company. Please refer to the Company’s most recent Forms 10-Q and 10-K and subsequent filings with the SEC for a further discussion of these risks and uncertainties. The Company disclaims any obligation or intent to update the forward-looking statements in order to reflect events or circumstances after the date of this release.

Company Contact:
Mark A. Featherstone, 
Chief Financial Officer of OPT 
Phone:
609-730-0400

Investor Relations Contact:
Andrew Barwicki
Phone:
516-662-9461

(ZFGN) Phase 3 Beloranib Trial in Prader-Willi Achieves Co-Primary Efficacy Endpoints

– bestPWS Study is the first Phase 3 pivotal trial to show significant weight-loss and improve hyperphagia-related behaviors in PWS patients-

-Statistically significant at both 2.4 mg and 1.8 mg dose levels-

-Company plans to discuss results and path forward for beloranib with the FDA-

-Conference call scheduled for 8:30 AM Eastern Time-

BOSTON, Jan. 20, 2016  — Zafgen (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, announced today positive efficacy results from the bestPWS ZAF-311 study, a pivotal, double-blind, placebo-controlled Phase 3 trial evaluating the safety and efficacy of beloranib, a MetAP2 inhibitor, in patients with Prader-Willi syndrome (PWS) during a six-month randomized treatment period. The clinical trial achieved its co-primary efficacy endpoints, as beloranib demonstrated a statistically significant reduction in both body weight and hyperphagia-related behaviors, making it the first investigational drug to demonstrate a positive impact on these two hallmark challenges in PWS.

Treatment with the 2.4 mg and the 1.8 mg doses of beloranib resulted in 9.45 percent (p<0.0001) and 8.20 percent (p<0.0001) reductions in body weight relative to placebo, respectively. Treatment with the 2.4 mg and the 1.8 mg doses of beloranib also resulted in reductions of hyperphagia-related behaviors of 7.0 units (p=0.0001) and 6.3 units (p=0.0003) relative to placebo, respectively, as measured by the Hyperphagia Questionnaire for Clinical Trials (HQ-CT).

“This clear efficacy outcome is a crucial first step in moving discussions forward with the Food and Drug Administration regarding continued development of beloranib,” stated Thomas Hughes, Ph.D., Chief Executive Officer of Zafgen. “While we take the previously reported adverse events very seriously, we now have the robust data to provide greater perspective on the benefit/risk relationship of beloranib in this high-risk patient population. We thank our investigators, and the patients and their families for participating in the bestPWS ZAF-311 clinical trial.”

PWS is the most common genetic cause of life-threatening obesity. Pathologic hunger-related behaviors, known as hyperphagia, dominate the lives of individuals with PWS, and drive patients to engage in problematic behaviors which can lead to excessive overeating, choking, and stomach rupture. Compounding the morbid obesity in PWS is slowed metabolism, psychiatric conditions including aggression, anxiety, and psychosis, higher risk for cardiopulmonary and metabolic co-morbidities; all of which contribute to a higher risk of obesity-related mortality.

“Prader-Willi syndrome significantly impacts the quality of life of affected individuals and their families, as it drives patients to engage in excessive overeating, or hyperphagia, and may also lead to morbid obesity, which can be life-threatening if not controlled,” said Merlin G. Butler, M.D., Ph.D., FFACMG, Professor of Psychiatry, Behavioral Sciences and Pediatrics, Director, Division of Research and Genetics, Department of Psychiatry, Behavioral Sciences and Pediatrics at the Kansas University Medical Center. “There are no treatment options for these life-limiting problems, so I believe the significant improvements seen in both hyperphagia and obesity in patients receiving beloranib during this six-month clinical trial are clinically meaningful and support a strong rationale for continued evaluation of beloranib as a potential treatment for PWS.”

On December 2, 2015, the Food and Drug Administration (FDA) notified Zafgen that the beloranib investigational new drug (IND) application had been placed on complete clinical hold due to an imbalance in severe venous thromboembolic events, including two patient deaths. In order to address the clinical hold, Zafgen plans to present to the FDA the efficacy and safety data from the bestPWS ZAF-311 study, data from the Phase 2b trial of beloranib in severe obesity complicated by type 2 diabetes, ZAF-203, expected later this quarter, and a proposal for a risk mitigation strategy for beloranib in PWS.

“We are actively working to better understand the mechanisms and incidence of underlying thromboembolic disease in PWS, as well as the potential impact of beloranib treatment on thrombosis in order to develop a strategy for risk mitigation in this underserved patient population,” Dr. Hughes said. “We plan to continue our dialog with the FDA given the robust efficacy results seen in the ZAF-311 trial.”

BestPWS ZAF-311 Efficacy and Safety Results

The bestPWS ZAF-311 study randomized 107 patients to receive twice-weekly subcutaneous injections of either 2.4 mg or 1.8 mg of beloranib or placebo. Seventy-four patients completed the full 26 weeks of treatment per the trial protocol, and 27 patients completed at least 75 percent of the randomized treatment period prior to the suspension of dosing in the trial in October 2015. There were six patients who discontinued early. The co-primary efficacy endpoints for this trial were improvement in hyperphagia-related behaviors and reduction in body weight. Patients in the trial were on average 20 years old, had an average BMI of 40 kg/m² and an average hyperphagia total score of 16.9, consistent with moderate to severe hyperphagia, at the beginning of randomized treatment. These baseline characteristics were well-balanced across the treatment arms. In agreement with the FDA, Zafgen has analyzed the data using a mixed model repeated measures (MMRM) approach to account for the missing endpoint data of the patients who did not complete the clinical trial.

Patients in the ZAF-311 trial were markedly obese at baseline. Patients randomized to receive placebo displayed substantial (4.15%) gain in body weight over the course of the six months of randomized treatment. Body weight gain in this patient population was anticipated, and typically occurs throughout life generally due to lack of effective treatments for managing obesity. Patients treated with beloranib, in contrast to placebo, lost weight, with the 2.4 mg dose arm displaying a 5.3 percent reduction from baseline, with a placebo-adjusted weight loss of 9.45 percent.

The HQ-CT is a PWS-specific study instrument that provides an assessment by caregivers of the food-seeking behaviors exhibited by patients. The scale provides a composite value from nine questions, each rated on a scale of zero to four units (total range of score of zero to 36). Patients in the ZAF-311 trial were enrolled only if their baseline HQ-CT total score was greater than 12 units, representing moderate-to-severe hyperphagia related behaviors at baseline. While hyperphagia-related behaviors were stable over six months of treatment in the placebo arm, both the 2.4 mg and 1.8 mg beloranib arms showed highly statistically significant reductions in HQ-CT total score, indicative of reduced hunger-associated behaviors.

The most common adverse events (AEs) were injection site bruising, aggression, and hyperphagia, generally of mild and transient nature. Of these, only injection site bruising was notable as being reported more frequently in patients taking beloranib compared to placebo. There were a total of five serious adverse events (SAEs); aggression (placebo, 2.4 mg beloranib), ankle fracture (placebo), mental status change (1.8 mg beloranib), and pulmonary embolism (1.8 mg beloranib). Four patients withdrew due to adverse events in the 1.8 mg beloranib treatment group (abnormal behavior, anxiety, mental status changes, and pulmonary embolism) and two patients in the 2.4 mg beloranib group (injection site pain and psychotic disorder). Many of these adverse events, specifically psychiatric disorders, are commonly observed as background comorbidities in PWS patients. At the end of the randomized treatment period, there were no clinically significant abnormal patterns regarding laboratory values, vital signs, or electrocardiography (ECG) findings. As previously disclosed, across the completed trials comprising the beloranib clinical program, there has been an association of venous thromboembolic events reported in patients treated with beloranib versus placebo, including one fatal case of pulmonary embolism (1.8 mg beloranib) during the randomized portion of the bestPWS study that was reported in October 2015. No other venous thromboembolic events were reported during the blinded randomized portion of the bestPWS study. As previously reported, a second patient death associated with pulmonary embolism (2.4 mg beloranib) and two cases of deep vein thrombosis (1.8 mg and 2.4 mg beloranib) occurred during the open-label extension portion of the bestPWS study. No other deaths have occurred in the course of the beloranib program.

Zafgen plans to present the full safety and efficacy data set from the bestPWS Phase 3 trial, including impact on body composition, cardiovascular disease risk markers, metabolic endpoints, and quality of life measures at upcoming medical meetings.

Conference Call Information

Zafgen will host an investor conference call today, January 20, 2016 at 8:30 a.m., Eastern Time, to discuss the trial results in more detail. Investors and other interested parties may participate by dialing (844) 824-7428 in the United States or (973) 500-2177 outside the United States. The call will also be webcast live on the Company’s website at http://ir.zafgen.com/events.cfm. You can access the replay for seven days by dialing (855) 859-2056 in the United States or (404) 537-3406 outside the United States and referencing conference ID number 32720188.

About Beloranib

Beloranib is a novel, first-in-class injectable small molecule therapy that works by inhibiting MetAP2, an enzyme that modulates the activity of key cellular processes that control metabolism. Once a person becomes obese, the body undergoes certain metabolic changes and becomes “programmed” to create and store more fat, making it much more difficult to reduce body weight. Beloranib is believed to help reduce hunger and restore balance to fat metabolism, enabling calories to once again be used as a productive energy source. Because beloranib works beyond just regulating hunger through the hypothalamus, it has the potential to be used in a variety of complex metabolic disorders such as Prader-Willi syndrome and hypothalamic injury associated obesity. Zafgen holds exclusive worldwide rights (exclusive of South Korea) for the development and commercialization of beloranib. Zafgen exclusively licensed beloranib from Chong Kun Dang Pharmaceutical Corporation (CKD Pharma) of South Korea.

About Prader-Willi Syndrome (PWS)

Prader-Willi syndrome (PWS), is the most common known genetic cause of life-threatening obesity. A dysfunctional signaling to the hypothalamus results in constant and unrelenting perception of starvation, driving patients with PWS to engage in problematic hunger-related behaviors, known as hyperphagia, and to gain excessive weight. As a result, many of those affected with PWS become morbidly obese and suffer significant mortality. Currently, there is no cure for this disease. Although the cause of PWS is complex, it results from a deletion or loss of function of a cluster of genes on the 15th chromosome. PWS typically causes low muscle mass and function, short stature, incomplete sexual development, and a chronic feeling of hunger that, when coupled with a metabolism that utilizes drastically fewer calories than normal, can lead to excessive eating and life-threatening obesity. PWS occurs in males and females equally and in all races, with the same incidence around the world. Prevalence estimates have ranged from 1:8,000 to 1:50,000.  Patients with PWS have a shortened life expectancy of approximately 32 years, as a result of an estimated three percent annual death rate for the PWS population.  Common causes of mortality in PWS include respiratory disease, cardiac disease, infection, choking, gastric rupture, and pulmonary embolism.

About Zafgen

Zafgen (Nasdaq:ZFGN) is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders. Zafgen is focused on developing novel therapeutics that treat the underlying biological mechanisms through the MetAP2 pathway. Beloranib, Zafgen’s lead product candidate, is a novel, first-in-class, twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in two rare diseases, Prader-Willi syndrome and obesity caused by hypothalamic injury, including craniopharyngioma-associated obesity; and severe obesity in the general population. Zafgen is also developing ZGN-839, a liver-targeted MetAP2 inhibitor, for the treatment of nonalcoholic steatohepatitis, or NASH, and abdominal obesity, as well as second-generation MetAP2 inhibitors. Zafgen aspires to improve the lives of patients through targeted treatments and has assembled a team accomplished in bringing therapies to patients with both rare and prevalent metabolic diseases.

Safe Harbor Statement

Various statements in this release concerning Zafgen’s future expectations, plans and prospects, including without limitation, Zafgen’s expectations regarding beloranib as a treatment for PWS, obesity caused by hypothalamic injury, including craniopharyngioma-associated obesity, and other forms of severe obesity, including severe obesity in patients with type 2 diabetes, Zafgen’s expectations with respect to the timing and success of its clinical trials of beloranib and its other product candidates, the expected requirements and timing of additional requirements for planned clinical trials, and the need for  additional clinical trials and pre-clinical studies, and Zafgen’s plans regarding commercialization of beloranib may constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements can be identified by terminology such as “anticipate,” “believe,” “could,” “could increase the likelihood,” “estimate,” “expect,” “intend,” “is planned,” “may,” “should,” “will,” “will enable,” “would be expected,” “look forward,” “may provide,” “would” or similar terms, variations of such terms or the negative of those terms. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Zafgen’s ability to obtain a release of the full clinical hold that the FDA placed on the investigational new drug application for beloranib, Zafgen’s ability to successfully demonstrate the efficacy and safety of beloranib and its other product candidates, the pre-clinical and clinical results for beloranib and its other product candidates, which may not support further development and marketing approval, actions of regulatory agencies, which may affect the initiation, timing and progress of preclinical studies and clinical trials, Zafgen’s ability to obtain, maintain and protect its intellectual property, Zafgen’s ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties, competition from others developing products for similar uses, Zafgen’s ability to manage operating expenses, Zafgen’s ability to obtain additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives, Zafgen’s dependence on third parties for development, manufacture, marketing, sales and distribution of products, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the section entitled “Risk Factors” in Zafgen’s most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in Zafgen’s subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Zafgen’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Zafgen explicitly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Media/Investor Relations Contact:

Zafgen, Inc.
Patricia Allen
Chief Financial Officer
617-648-9792

Argot Partners
Investor Relations
David Pitts or Laura Perry
212-600-1902
david@argotpartners.com
laura@argotpartners.com

Spectrum Science
Media Relations
Susan Francis
609-529-0676
sfrancis@spectrumscience.com

(MOXC) Enters Exclusive Agreement, Development Partnership With Xinhua Media Affiliate

(SKLN) ARIN Partners With Skyline Medical to Promote Imaging and Radiology

MINNEAPOLIS, Jan. 19, 2016  — Skyline Medical Inc. (Nasdaq:SKLN) (Nasdaq:SKLNU) (“Skyline” or the “Company”) announced today that, as part of the continuing expansion of its sales strategy, the Company has entered into a partnership with the Association for Radiologic & Imaging Nursing (“ARIN”) to market Skyline products and services to medical professionals performing paracentesis and thoracentesis procedures.

Josh Kornberg, President and CEO of Skyline Medical, commented, “Our research has shown that most radiology and imaging rooms do not currently use, nor are they aware of automated fluid disposal technology, despite the major potential safety and cost benefits. As it is the nurses and technologists that often perform these procedures and can help influence purchasing decisions, we expect our partnership with ARIN to create new sales opportunities.”

Under the terms of the partnership, Skyline Medical will sponsor ARIN and ARIN will provide Skyline Medical with access to nurses in the imaging and radiology space. In conjunction with their partnership, Skyline Medical will have the opportunity to attend the ARIN Spring Convention in Vancouver on April 3. Skyline’s sales representatives will demonstrate Skyline products to nurses, technologists and other decision makers in the industry.

About ARIN
The Association for Radiologic & Imaging Nursing (ARIN) was founded in 1981 as the professional organization representing nurses who practice in the diagnostic, neuro/cardiovascular, interventional, ultrasonography, computerized tomography, nuclear medicine, magnetic resonance, and radiation oncology areas.

ARIN’s goal is to partner with strategic organizations that can enhance the radiology and imaging profession in addition to providing new benefits to ARIN’s members. New partnership arrangements are vetted thoroughly for any conflicts of interest or standards outside of our core purpose. As ARIN grows, we will continue to provide additional educational opportunities and services for our membership through strategic alliances from within the nursing community.

About Skyline Medical Inc.
Skyline Medical Inc. produces a fully automated, patented, FDA-cleared, waste fluid disposal system that virtually eliminates staff exposure to blood, irrigation fluid and other potentially infectious fluids found in the healthcare environment. Antiquated manual fluid handling methods — which require hand carrying and emptying filled fluid canisters and glass bottles — present an exposure risk and potential liability. For additional information, please visit: www.skylinemedical.com.

Forward-looking Statements:
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company’s business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include, among other things, uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance; the Company’s ability to implement its long range business plan for various applications of its technology; the Company’s ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company’s technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, which are available for review at www.sec.gov.

Contacts:
ARIN Contact 
Bruce Boulter
Executive Director
Association for Radiologic and Imaging Nursing
866-486-2762
bruce.boulter@arinursing.org

Skyline Investor Relations Contact:
Garth Russell 
KCSA Strategic Communications
212-896-1250 
skyline@kcsa.com

(AEZS) Phase 3 Trial of Macrilen Confirmatory Meeting Successful

Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the “Company”) announced today that it concluded a successful meeting of the clinical investigators for the confirmatory Phase 3 trial of Macrilen™ (macimorelin), a novel orally-active ghrelin agonist for use in evaluating adult growth hormone deficiency (“AGHD”). As a result, the Company is confident that it will complete the confirmatory trial by year-end 2016.

Dr. Richard Sachse, the Company’s Chief Scientific Officer stated, “On January 16, we held an Investigators’ Meeting for our multi-center confirmatory Phase 3 clinical trial of Macrilen™. The purpose of the meeting was to review Macrilen™ with the investigators, as well as the clinical trial protocol. The 77 investigators and site personnel who attended the meeting included Jose Manuel Garcia, MD, PhD, Associate Professor of Medicine at University of Washington School of Medicine, Seattle, who is serving as coordinating investigator. Dr. Garcia expressed his commitment to the development of Macrilen™ because of the medical need for such a convenient test in the absence of an FDA-approved diagnostic test for AGHD.”

Patients who are believed to have AGHD are now very often evaluated by means of the insulin tolerance test (“ITT”). The ITT is the historical gold standard for the evaluation of AGHD because of its high sensitivity and specificity. However, the ITT is inconvenient to the patients and physicians and contra-indicated in certain patients, such as patients with coronary heart disease or seizure disorder, because it requires the patient to experience hypoglycemia to obtain a result. Some physicians will not induce full hypoglycemia, intentionally compromising accuracy to increase safety and comfort for the patient. Furthermore, administration of the ITT is expensive because the patient must be constantly monitored by a physician for the 2-4 hour duration of the test and the test must be administered in a setting where emergency equipment is available and where the patient may be quickly hospitalized. The ITT is not used for patients with co-morbidities, such as CV, seizure disorder or a history of brain cancer or for patients who are elderly and frail, due to safety concerns.

The Company believes that Macrilen™, if it is approved, is likely to be rapidly adopted by physicians as the preferred means of evaluating AGHD for the following reasons:

• it is safer than the ITT because it does not require the patient to become hypoglycemic;
• Macrilen™ is administered orally, while the ITT requires an intravenous infusion of insulin;
• the evaluation of AGHD using Macrilen™ is much less time consuming and labor intensive than the ITT and, therefore, it is less expensive to conduct; and
• the evaluation can be conducted in the physician’s office rather than in a hospital setting.

About the Study

The confirmatory Phase 3 clinical study of Macrilen™, entitled Confirmatory validation of oral macimorelin as a growth hormone (GH) stimulation test (ST) for the diagnosis of adult growth hormone deficiency (AGHD) in comparison with the insulin tolerance test (ITT), is designed as a two-way crossover study with the insulin tolerance test as the benchmark comparator and will involve some 30 sites in the United States and Europe. The study population will consist of approximately 110 subjects (at least 55 ITT-positive and 55 ITT-negative) with a medical history documenting risk factors for AGHD, and will include a spectrum of subjects from those with a low risk of having AGHD to those with a high risk of having the condition. The primary endpoint is validation of a single oral dose of macimorelin for the diagnosis of AGHD, using the ITT as a comparator. Based on meetings with the US Food and Drug Administration (“FDA”) as well as the European Medicines Agency (“EMA”) and subsequent written scientific advice, the Company believes that the study meets the FDA’s and the EMA’s study-design expectations allowing US and European approval, if successful. As of the date of this release, five patients at three separate centers have been enrolled in the study. For more details on the trial, please consult this link:

https://www.clinicaltrial.gov/ct2/show/NCT02558829?term=macimorelin&rank=1.

Based on the current rate of enrollment, the Company expects the confirmatory Phase 3 clinical study of Macrilen™ to be concluded by the end of 2016. The Company further expects to be able to submit a New Drug Application for Macrilen™ to the FDA by mid-year 2017 and, if the study is successful in meeting its primary endpoint, to obtain approval of the drug by year-end 2017.

About Macrilen^TM (macimorelin)

Macimorelin, a ghrelin agonist, is a novel orally-active small molecule that stimulates the secretion of growth hormone. Macimorelin, under the trade name Macrilen^TM, has been granted orphan drug designation by the FDA for diagnosis of AGHD. The Company owns the worldwide rights to this novel patented compound.

About AGHD

AGHD affects approximately 75,000 adults across the US, Canada and Europe. Growth hormone not only plays an important role in growth from childhood to adulthood, but also helps promote a hormonally-balanced health status. AGHD mostly results from damage to the pituitary gland. It is usually characterized by a reduction in bone mineral density, lean body mass, exercise capacity, and overall quality of life.

About Aeterna Zentaris Inc.

Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women’s health. We are engaged in drug development activities and in the promotion of products for others. We are now conducting Phase 3 studies of two internally developed compounds. The focus of our business development efforts is the acquisition of licenses to products that are relevant to our therapeutic areas of focus. We also intend to license out certain commercial rights of internally developed products to licensees in territories where such out-licensing would enable us to ensure development, registration and launch of our product candidates. Our goal is to become a growth-oriented specialty biopharmaceutical company by pursuing successful development and commercialization of our product portfolio, achieving successful commercial presence and growth, while consistently delivering value to our shareholders, employees and the medical providers and patients who will benefit from our products. For more information, visit www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the US Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to statements preceded by, followed by, or that include the words “expects,” “believes,” “intends,” “anticipates,” and similar terms that relate to future events, performance, or our results. Forward-looking statements involve known and unknown risks and uncertainties that could cause the Company’s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects and clinical trials, the successful and timely completion of clinical studies, the risk that safety and efficacy data from any of our Phase 3 trials may not coincide with the data analyses from previously reported Phase 1 and/or Phase 2 clinical trials, the ability of the Company to efficiently commercialize one or more of its products or product candidates, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process, the ability to protect our intellectual property, the potential of liability arising from shareholder lawsuits and general changes in economic conditions. Investors should consult the Company’s quarterly and annual filings with the Canadian and US securities commissions for additional information on risks and uncertainties relating to forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or by applicable law.

Aeterna Zentaris Inc.
Philip A. Theodore
Senior Vice President
843-900-3223
ir@aezsinc.com

(ANY) Multi-Site National Call Center Selects Sphere 3D’s Hybrid Cloud Solutions

Surpass, LLC call centers to virtualize workloads with V3 and Glassware 2.0, increase onsite storage efficiencies with SnapServer, and provide Cloud Storage via SnapCLOUD on Microsoft Azure

San Jose, California–(January 19, 2016) – Sphere 3D Corp. (NASDAQ: ANY), a containerization, virtualization and data management solutions provider, today announced that Surpass, LLC (“Surpass”), a national call center headquartered in Lynchburg, VA will upgrade two of its call centers with Sphere 3D’s hybrid cloud offerings.

“We have worked very hard over the past year to enhance, refine and align our products. Our strategy of vertically integrating our portfolio to deliver turnkey hybrid cloud offerings now allows us to provide highly impactful solutions to our customers” said Peter Bookman, Global Strategist at Sphere 3D. “I am pleased that we were selected by Surpass, and look forward to assisting them to scale quickly and improve their workflow through the type of innovation that elevates our solutions above those offered by our competitors.”

“At Surpass, we believe the key to our growth is providing world class service to our clients while maximizing operating efficiencies. We are excited to bring Sphere 3D’s hybrid cloud solutions into our newest 80-seat call center located in Lynchburg, VA. Additionally, we plan on leveraging their portfolio of services to modernize our current facility without replacing any of our existing hardware,” said Ken Mnemcovich, President at Surpass, LLC. “Sphere 3D’s portfolio supports the flexibility to purchase in a bundled price or a la carte depending on our real time requirements. We anticipate our callers’ average call time (ACT) will shorten and deliver optimal results for our clients. We now have the tools we need to support our virtual desktops while providing secure access to our client data both onsite and in the Microsoft Azure cloud.”

Surpass will deploy a complete hybrid cloud solution that includes Sphere 3D’s V3™ virtual desktop appliances, integrated with software from VMware and managed by Sphere 3D’s Desktop Cloud Orchestrator™ (DCO); 80 seats of Glassware 2.0™ containers for applications virtualization; SnapServer® physical storage for shared storage; and the SnapCLOUD™ virtual storage service in Microsoft Azure.

Surpass will be able to take advantage of a comprehensive cloud solution that offers simple deployment and management while maintaining the ability to scale out as needed. Although this approach provides a complete hybrid cloud experience, it’s delivered at a low total cost of ownership; with the initial call center deployment costing just over $150,000 U.S.

About Sphere 3D

Sphere 3D Corp. (NASDAQ: ANY) delivers containerization and virtualization technologies along with data management products that enable workload-optimized solutions. We achieve this through a combination of containerized applications, virtual desktops, virtual storage and physical hyper-converged platforms. Sphere 3D’s value proposition is simple and direct—we allow organizations to deploy a combination of public, private or hybrid cloud strategies while backing them up with state of the art storage solutions. Sphere 3D, along with its wholly-owned subsidiaries Overland Storage and Tandberg Data, has a strong portfolio of brands including Glassware 2.0™, SnapCLOUD™, SnapScale®, SnapServer®, V3, RDX®, and NEO®. For more information, visit www.sphere3d.com.

# # #

Media Contacts:
Eileen Elam
Sphere 3D
408-283-4734
media.relations@sphere3d.com

Anna Johnston
BWW Communications
+44-1491-636393
anna.johnston@bwwcomms.com

Investor Relations Contact:
Mike Bishop
The Blueshirt Group
+1 415-217-4968
mike@blueshirtgroup.com

Safe Harbor Statement

This press release may contain forward-looking statements that involve risks, uncertainties, and assumptions that are difficult to predict. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties including, without limitation, unforeseen changes in the course of Sphere 3D’s business or the business of its wholly-owned subsidiaries, including, without limitation, Overland Storage and Tandberg Data; any failure in the functionality or performance of our products; the level of success of our collaborations and business partnerships; possible actions by customers, partners, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in Sphere 3D’s periodic reports contained in our Annual Information Form and other filings with Canadian securities regulators (www.sedar.com) and in prior periodic reports filed with the United States Securities and Exchange Commission (www.sec.gov). Sphere 3D undertakes no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.